1
|
Joseph L, De Luna G, Bernit E, Cougoul P, Santin A, Faucher B, Habibi A, Garou A, Loko G, Mattioni S, Manceau S, Arlet JB, Lionnet F. A study of 28 pregnant women with sickle cell disease and COVID-19: elevated maternal and fetal morbidity rates. Haematologica 2024; 109:1562-1565. [PMID: 37855041 PMCID: PMC11063858 DOI: 10.3324/haematol.2023.283300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 10/13/2023] [Indexed: 10/20/2023] Open
Abstract
Not available.
Collapse
Affiliation(s)
- Laure Joseph
- Biotherapy Department, French National Sickle Cell Disease Referral Center, Clinical Investigation Center, Hopital Necker, Labex GR-Ex, Assistance-Publique Hopitaux de Paris, Paris.
| | - Gonzalo De Luna
- Unite des maladies genetiques du globule rouge and Etablissement Francais du Sang, Hopital Henri Mondor, Assistance-Publique Hopitaux de Paris, Creteil
| | - Emmanuelle Bernit
- Antilles-Guyane Reference Center for Sickle-Cell Disease, Thalassemia and Other Red Blood Cell Disorders, Pointe a Pitre, Guadeloupe
| | - Pierre Cougoul
- Institut Universitaire du Cancer Toulouse Oncopole, Medecine Interne, Toulouse
| | - Aline Santin
- Department of Internal Medicine, Reference Center of Sickle cell Anemia, University Hospital Center of Tenon, Sorbonne University, Assistance-Publique Hopitaux de Paris, Paris
| | - Benoit Faucher
- Department of Internal Medicine, Aix Marseille Universite, Assistance-Publique Hopitaux de Marseille, Hopital de la Timone, Marseille
| | - Anoosha Habibi
- Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, Assistance-Publique Hopitaux de Paris, U-PEC, Creteil
| | - Alain Garou
- Sickle Cell Referral Center, Centre Hospitalier de Mayotte, Mayotte
| | - Gylna Loko
- Sickle Cell Referral Center, Martinique Hospital, Martinique
| | - Sarah Mattioni
- Department of Internal Medicine, Reference Center of Sickle cell Anemia, University Hospital Center of Tenon, Sorbonne University, Assistance-Publique Hopitaux de Paris, Paris
| | - Sandra Manceau
- Biotherapy Department, French National Sickle Cell Disease Referral Center, Clinical Investigation Center, Hopital Necker, Labex GR-Ex, Assistance-Publique Hopitaux de Paris, Paris
| | - Jean Benoit Arlet
- Internal Medicine Department, French National Sickle Cell Disease Referral Center, Georges Pompidou European Hospital, Assistance Publique-Hopitaux de Paris, Paris
| | - François Lionnet
- Department of Internal Medicine, Reference Center of Sickle cell Anemia, University Hospital Center of Tenon, Sorbonne University, Assistance-Publique Hopitaux de Paris, Paris
| |
Collapse
|
2
|
Allali S, Galactéros F, Oevermann L, Cannas G, Joseph L, Loko G, Elenga N, Benkerrou M, Etienne-Julan M, Castex MP, Brousse V, de Montalembert M. Hydroxyurea is associated with later onset of acute splenic sequestration crisis in sickle cell disease: Lessons from the European Sickle Cell Disease Cohort-Hydroxyurea (ESCORT-HU) study. Am J Hematol 2024; 99:555-561. [PMID: 38247384 DOI: 10.1002/ajh.27214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Revised: 12/22/2023] [Accepted: 01/01/2024] [Indexed: 01/23/2024]
Abstract
Acute splenic sequestration crisis (ASSC) is a potentially life-threatening complication of sickle cell disease (SCD), typically occurring in young patients under 5 years of age, with a median age at first episode of less than 2 years. Because a beneficial effect of hydroxyurea (HU) on spleen perfusion and splenic function has been suspected, we hypothesized that HU treatment might be associated with later onset of ASSC in patients with SCD. To investigate this hypothesis, we analyzed data from the ESCORT-HU study on a large cohort of patients with SCD receiving HU, enrolled between January 2009 and June 2017 with a follow-up of 7309 patient-years of observation. The median age at ASSC of the 14 patients who experienced a first episode of ASSC during the study period was 8.0 [IQR: 5.0-24.1] years. The median age at HU initiation was significantly lower in these 14 patients (4.8 [IQR: 3.3-18.7] years) compared to the 1664 patients without ASSC (19.9 [8.8-33.4] years, p = .0008). These findings suggest that ASSC may occur at an unusually late age in patients receiving HU, possibly reflecting longer preservation of spleen perfusion and function secondary to early initiation of HU. Further studies are needed to better characterize the effects of HU on spleen perfusion/function and on the occurrence of ASSC in patients with SCD (ClinicalTrials.gov identifier: NCT02516579; European registry ENCEPP/SDPP/10565).
Collapse
Affiliation(s)
- Slimane Allali
- Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France
| | - Frédéric Galactéros
- Department of Internal Medicine, Sickle Cell Referral Center, Henri-Mondor University Hospital-UPEC, AP-HP, Créteil, France
| | - Lena Oevermann
- Department of Pediatric Oncology and Hematology, Charité University Medicine, Berlin and Berlin Institute of Health, Berlin, Germany
| | - Giovanna Cannas
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Médecine Interne, Centre de Référence Constitutif: Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Lyon, France
| | - Laure Joseph
- Biotherapy Department, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France
| | - Gylna Loko
- Centre Hospitalier Universitaire de Martinique, Centre de Référence Constitutif: Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Érythropoïèse des Antilles et de la Guyane, Le Lamentin, Martinique, France
| | - Narcisse Elenga
- Centre Hospitalier de Cayenne, Centre de Référence Constitutif: Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Cayenne, French Guiana
| | - Malika Benkerrou
- Centre de Référence MCGRE, Service d'Hématologie-Immunologie, AP-HP, Hôpital Robert Debré, Inserm, UMR-1123 ECEVE, Université Paris Cité, Paris, France
| | - Maryse Etienne-Julan
- Unité Transversale de la Drépanocytose, Centre de Référence Maladies Rares pour la Drépanocytose aux Antilles-Guyane, CHU de Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe, France
| | - Marie-Pierre Castex
- Pediatric Oncology Immunology Hematology Unit, Children's University Hospital - Toulouse University Hospital, Toulouse, France
| | - Valentine Brousse
- Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France
- Centre de Référence MCGRE, Service d'Hématologie-Immunologie, AP-HP, Hôpital Robert Debré, Inserm, UMR-1123 ECEVE, Université Paris Cité, Paris, France
| | - Mariane de Montalembert
- Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France
| |
Collapse
|
3
|
Broccia MV, Vergier J, Benoit A, Huguenin Y, Lambilliotte A, Castex MP, Gourdon S, Ithier G, Kebaili K, Rohrlich P, Pondarre C, Chamouine A, Simon P, Kpati KPA, Allali S, Baron-Joly S, Bayart S, Billaud N, Brousse V, Dumesnil C, Garnier N, Guichard I, Joseph L, Kamdem A, Maitre J, Mathey C, Paillard C, Phulpin A, Renard C, Stoven C, Touati M, Trochu C, Nafissi SM, Badens C, Szepetowski S, Thuret I. Pubertal development of transfusion-dependent thalassemia patients in the era of oral chelation with deferasirox: results from the French registry. Haematologica 2024. [PMID: 38385265 DOI: 10.3324/haematol.2023.283610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Indexed: 02/23/2024] Open
Abstract
Not available.
Collapse
Affiliation(s)
- Mathilde Veneziano Broccia
- Service d'Hematologie, Immunologie et Oncologie Pediatrique, Hopital La Timone Enfants, AP-HM, Marseille, France; Centre de Reference MCGRE, Service d'Hematologie, Immunologie et Oncologie Pediatrique, Hopital La Timone Enfants, AP-HM, Marseille.
| | - Julia Vergier
- Service de Pediatrie Multidisciplinaire, Hopital de la Timone Enfants, AP-HM, Marseille
| | - Audrey Benoit
- National Thalassemia Registry (NaThalY), Service de Genetique, Hopital La Timone Enfants, APHM, Marseille
| | - Yoann Huguenin
- Service d'Oncologie et d'Hematologie Pediatrique, Hopital Pellegrin, CHU de Bordeaux, Bordeaux
| | - Anne Lambilliotte
- Service d'Hematologie et d'Oncologie Pediatrique, Centre Hospitalo-Universitaire de Lille, Lille
| | | | - Stephanie Gourdon
- Service d'Oncologie et Hematologie Pediatrique, Centre Hospitalier Universitaire de La Reunion, Saint Denis
| | - Ghislaine Ithier
- Centre de Reference MCGRE, Unite d'Hematologie, Hopital Robert Debre, Assistance Publique-Hopitaux de Paris (AP-HP), Paris
| | - Kamila Kebaili
- Institut d'Hematologie et d'Oncologie Pediatrique, Hospices Civils de Lyon, Lyon
| | | | - Corinne Pondarre
- Centre de Reference MCGRE, Service de pediatrie, centre hospitalier intercommunal de Creteil, Creteil ; Inserm U955, Universite Paris-XII, Creteil
| | - Abdourahim Chamouine
- Centre de Reference MCGRE, Service de Pediatrie, Centre Hospitalier de Mayotte, Mamoudzou,Mayotte
| | - Pauline Simon
- Service d'Hematologie Pediatrique, CHU de Besanc_on, Besanc_on
| | - Kokou Placide Agbo Kpati
- Service de Pediatrie-Neonatologie-Medecine de l'Adolescent, GHEF-Site de Marne La Vallee, Jossigny
| | - Slimane Allali
- Centre de Reference MCGRE, service de Pediatrie Generale, Hopital Necker-Enfants malades, AP-HP, Paris
| | | | - Sophie Bayart
- Service d'Hematologie Pediatrique, CHU de Rennes, Rennes
| | | | - Valentine Brousse
- Centre de Référence MCGRE, Service d'Hematologie-Immunologie, Hopital Robert Debre, AP-HP, Paris
| | | | - Nathalie Garnier
- Institut d'Hematologie et d'Oncologie Pediatrique, Hospices Civils de Lyon, Lyon
| | | | - Laure Joseph
- Centre de Reference MCGRE, CIC Biotherapie, Hopital Necker-Enfants malades, AP-HP, Paris France
| | - Annie Kamdem
- Centre de Reference MCGRE, Service de Pediatrie, Centre Hospitalier Intercommunal de Creteil (CHIC), Creteil
| | | | - Catherine Mathey
- Service d'Hematologie, Immunologie et Oncologie Pediatrique, Hopital La Timone Enfants, AP-HM, Marseille
| | - Catherine Paillard
- Service d'Hematologie et d'Oncologie Pediatrique, Hopital Hautepierre, Strasbourg
| | - Aurelie Phulpin
- Service d'Onco-hematologie Pediatrique, CHRU Nancy, Vandoeuvre les Nancy
| | - Cecile Renard
- Institut d'Hematologie et d'Oncologie Pediatrique, Hospices Civils de Lyon, Lyon
| | - Cecile Stoven
- Service de Pediatrie, CHU La Reunion, Groupe Hospitalier Sud Reunion
| | | | | | | | - Catherine Badens
- National Thalassemia Registry (NaThalY), Service de Genetique, Hopital La Timone Enfants, APHM, Marseille
| | - Sarah Szepetowski
- Service d'Hematologie, Immunologie et Oncologie Pediatrique, Hopital La Timone Enfants, AP-HM, Marseille, France; Centre de Reference MCGRE, Service d'Hematologie, Immunologie et Oncologie Pediatrique, Hopital La Timone Enfants, AP-HM, Marseille
| | - Isabelle Thuret
- Service d'Hematologie, Immunologie et Oncologie Pediatrique, Hopital La Timone Enfants, AP-HM, Marseille, France; Centre de Reference MCGRE, Service d'Hematologie, Immunologie et Oncologie Pediatrique, Hopital La Timone Enfants, AP-HM, Marseille
| |
Collapse
|
4
|
Joseph L, Driessen M. A comprehensive view of pregnancy in patients with sickle cell disease in high-income countries: the need for robust data and further decline in morbidity and mortality. Lancet Haematol 2024; 11:e75-e84. [PMID: 38135375 DOI: 10.1016/s2352-3026(23)00310-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 10/06/2023] [Accepted: 10/09/2023] [Indexed: 12/24/2023]
Abstract
Sickle cell disease is a major public health concern due to its prevalence and associated morbidities. In high-income countries, diagnosis and treatment advancements have extended patient's lives and enabled women to embrace motherhood. Although the provision of care in specialist centres has reduced maternal-fetal complication rates, the mortality rate among pregnant women with sickle cell disease remains disproportionately high. Complications arise from vaso-occlusive events, worsening organ damage, thrombotic risks, infections, and pregnancy-related issues, such as pre-eclampsia, premature birth, small-for-gestational-age, and pregnancy loss. Effective management during pregnancy includes preconception planning, genetic counselling, education, and collaborative care. There is no consensus on the overall approach to managing pregnant women with sickle cell disease; however, fostering a collaborative relationship between health-care professionals and researchers is crucial for advancing the understanding and management of this illness. The disparities in health-care outcomes associated with ethnicity and economic insecurity affect patients with sickle cell disease but have not been examined extensively. Hence, health-care personnel need sufficient training to address these issues alongside broader societal efforts to confront racism and discrimination. Comprehensive national and global action plans are required to address the multifaceted challenges of sickle cell disease.
Collapse
Affiliation(s)
- Laure Joseph
- Biotherapy Department, French National Sickle Cell Referral Centre, Biotherapy Clinical Investigation Centre, Hôpital Necker-Enfant Malades, Assistance-Publique Hôpitaux de Paris, Paris, France.
| | - Marine Driessen
- Department of Obstetrics and Fetal Medicine, Hôpital Necker-Enfant Malades, Assistance-Publique Hôpitaux de Paris, Paris, France
| |
Collapse
|
5
|
Joseph L, Manceau S, Borderie D, Patrat C, Arlet JB, Meunier B, Cavazzana M, Santulli P, Barraud-Lange V. Detrimental effects of sickle cell disease and hydroxycarbamide on ovarian reserve but uncertain impact on fertility. Blood Adv 2023; 7:4794-4798. [PMID: 36989137 PMCID: PMC10469061 DOI: 10.1182/bloodadvances.2022008859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 03/17/2023] [Accepted: 03/17/2023] [Indexed: 03/30/2023] Open
Affiliation(s)
- Laure Joseph
- Biotherapy Department, French National Sickle Cell Referral Center, Clinical
Investigation Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris,
France
| | - Sandra Manceau
- Biotherapy Department, French National Sickle Cell Referral Center, Clinical
Investigation Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris,
France
- Laboratory of Excellence on Red Blood Cell Labex GR-Ex, Paris,
France
| | - Didier Borderie
- University of Paris Cité, Paris, France
- Automated Biological Diagnosis Department, AP-HP.Centre-University of Paris
Cité, Cochin Hospital, Paris, France
| | - Catherine Patrat
- University of Paris Cité, Paris, France
- Department of Reproductive Biology CECOS, AP-HP.Centre-University of Paris
Cité, Cochin Hospital, Paris, France
| | - Jean Benoit Arlet
- Internal Medicine Department, French National Sickle Cell Referral Center,
Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris,
France
| | - Benoit Meunier
- Biotherapy Department, French National Sickle Cell Referral Center, Clinical
Investigation Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris,
France
| | - Marina Cavazzana
- Biotherapy Department, French National Sickle Cell Referral Center, Clinical
Investigation Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris,
France
- INSERM U1163, CNRS 8254, Institut IMAGINE, Hôpital Necker,
Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Pietro Santulli
- University of Paris Cité, Paris, France
- Department of Gynecology Obstetrics II and Reproductive Medicine,
AP-HP.Centre-University of Paris Cité, Cochin Hospital, Paris, France
- Department “Development, Reproduction and Cancer” Institut Cochin, INSERM
U1016, Paris, France
| | - Virginie Barraud-Lange
- University of Paris Cité, Paris, France
- Department of Reproductive Biology CECOS, AP-HP.Centre-University of Paris
Cité, Cochin Hospital, Paris, France
- Department “Development, Reproduction and Cancer” Institut Cochin, INSERM
U1016, Paris, France
| |
Collapse
|
6
|
Derdevet J, Ranque B, Khimoud D, Joseph L, Michon A, Flamarion E, Lafont E, Corbasson A, Pouchot J, Arlet JB, Cheminet G. Efficacy of COVID-19 vaccination in adult patients with sickle cell disease during the Omicron wave in France. Eur J Haematol 2023; 111:509-512. [PMID: 37380177 DOI: 10.1111/ejh.14034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2023] [Revised: 06/18/2023] [Accepted: 06/19/2023] [Indexed: 06/30/2023]
Affiliation(s)
- Julien Derdevet
- Internal Medicine Department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Brigitte Ranque
- Internal Medicine Department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
- Faculty of Medicine, Université Paris Cité, Paris, France
- Université Paris Cité, Inserm UMR-S970, Paris, France
| | - Djamal Khimoud
- Internal Medicine Department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Laure Joseph
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Adrien Michon
- Internal Medicine Department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Edouard Flamarion
- Internal Medicine Department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Emmanuel Lafont
- Internal Medicine Department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anne Corbasson
- Internal Medicine Department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jacques Pouchot
- Internal Medicine Department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
- Faculty of Medicine, Université Paris Cité, Paris, France
| | - Jean-Benoît Arlet
- Internal Medicine Department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
- Faculty of Medicine, Université Paris Cité, Paris, France
- Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France
- INSERM U1163, CNRS 8254, Institut IMAGINE, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Geoffrey Cheminet
- Internal Medicine Department, French National Sickle Cell Referral Center, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
- Faculty of Medicine, Université Paris Cité, Paris, France
| |
Collapse
|
7
|
Joseph L, Arlet JB, Bernaudin F, Dhédin N. [Therapeutic approaches in sickle cell disease]. Rev Prat 2023; 73:535-539. [PMID: 37309792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
THERAPEUTIC APPROACHES IN SICKLE CELL DISEASE. Sickle cell disease, the most common genetic disease in France, is still burdened with morbidity and early mortality before the age of 50. When the first-line treatment, hydroxyurea, is insufficient or in the case of organic damage(s) (in particular cerebral vasculopathy), a therapeutic intensification must be considered. New molecules are now available, such as voxelotor and crizanlizumab, but only hematopoietic stem cell (HSC) transplantation can cure the disease. Allogeneic HSC transplantation during childhood with a sibling donor is the reference but it is now possible to perform this procedure in adults with a reduced pre-transplant conditioning. Gene therapy, which consists of an autograft of genetically modified HSCs, has obtained promising results but has not yet demonstrated a complete cure of the disease (protocols underway). The toxicity of myeloablative conditioning (used in pediatrics or for gene therapy), particularly the sterility induced, and the risk of graft-versushost disease (for allogeneic transplantation) are limiting factors of these treatments.
Collapse
Affiliation(s)
| | - Jean-Benoît Arlet
- Université Paris-Cité, France AP-HP, Hôpital européen Georges-Pompidou, DMU Endromed, service de médecine interne, Centre national de référence des syndromes drépanocytaires majeurs, Paris, France
| | - Françoise Bernaudin
- Centre de recherche clinique, Hôpital intercommunal de Créteil, Créteil, France. Présidente de l'association Drepagreffe
| | - Nathalie Dhédin
- Unité d'hématologie adolescents et jeunes adultes, hôpital Saint-Louis, Paris, France
| |
Collapse
|
8
|
Speel EJ, Radonic T, Dafni U, Thunnissen E, Rüschoff J, Kowalski J, Kerr K, Bubendorf L, Valero IS, Joseph L, Navarro A, Monkhorst K, Madsen L, Losa JH, Biernat W, Dellaporta T, Kammler R, Peters S, Stahel R, Finn S. 191P ROS1 fusions in resected stage I-III adenocarcinoma (ADC): A Lungscape ETOP study. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00444-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
9
|
Tennenbaum J, Volle G, Pouchot J, Joseph L, Khimoud D, Ranque B, Arlet JB. Increased risk of venous thromboembolism in splenectomized patients with sickle cell disease. Br J Haematol 2023; 201:793-796. [PMID: 36916494 DOI: 10.1111/bjh.18743] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 02/12/2023] [Accepted: 02/27/2023] [Indexed: 03/16/2023]
Affiliation(s)
- Juliette Tennenbaum
- French National Reference Center for sickle cell disease, thalassaemia and other red blood cell and erythropoiesis disorders, Department of Internal Medicine, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris-Cité University Paris, Paris, France
| | - Geoffroy Volle
- Department of Internal Medicine, Henri-Mondor Hospital, AP-HP, Paris Est University, Créteil, France
| | - Jacques Pouchot
- French National Reference Center for sickle cell disease, thalassaemia and other red blood cell and erythropoiesis disorders, Department of Internal Medicine, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris-Cité University Paris, Paris, France
| | - Laure Joseph
- Reference Center for sickle cell disease, thalassemia and other red blood cell and erythropoiesis disorders, Biotherapy department, Necker Hospital, AP-HP, Paris-Cité University, Paris, France.,Laboratory of Excellence GR-Ex, Paris-Cité University, Paris, France
| | - Djamal Khimoud
- French National Reference Center for sickle cell disease, thalassaemia and other red blood cell and erythropoiesis disorders, Department of Internal Medicine, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris-Cité University Paris, Paris, France
| | - Brigitte Ranque
- French National Reference Center for sickle cell disease, thalassaemia and other red blood cell and erythropoiesis disorders, Department of Internal Medicine, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris-Cité University Paris, Paris, France.,Laboratory of Excellence GR-Ex, Paris-Cité University, Paris, France
| | - Jean-Benoît Arlet
- French National Reference Center for sickle cell disease, thalassaemia and other red blood cell and erythropoiesis disorders, Department of Internal Medicine, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris-Cité University Paris, Paris, France.,Laboratory of Excellence GR-Ex, Paris-Cité University, Paris, France.,INSERM U1163, CNRS 8254, IMAGINE Institute, Paris-Cité University, Paris, France
| |
Collapse
|
10
|
Hardouin G, Antoniou P, Martinucci P, Felix T, Manceau S, Joseph L, Masson C, Scaramuzza S, Ferrari G, Cavazzana M, Miccio A. Adenine base editor-mediated correction of the common and severe IVS1-110 (G>A) β-thalassemia mutation. Blood 2023; 141:1169-1179. [PMID: 36508706 PMCID: PMC10651780 DOI: 10.1182/blood.2022016629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Revised: 11/15/2022] [Accepted: 11/30/2022] [Indexed: 12/14/2022] Open
Abstract
β-Thalassemia (BT) is one of the most common genetic diseases worldwide and is caused by mutations affecting β-globin production. The only curative treatment is allogenic hematopoietic stem/progenitor cells (HSPCs) transplantation, an approach limited by compatible donor availability and immunological complications. Therefore, transplantation of autologous, genetically-modified HSPCs is an attractive therapeutic option. However, current gene therapy strategies based on the use of lentiviral vectors are not equally effective in all patients and CRISPR/Cas9 nuclease-based strategies raise safety concerns. Thus, base editing strategies aiming to correct the genetic defect in patients' HSPCs could provide safe and effective treatment. Here, we developed a strategy to correct one of the most prevalent BT mutations (IVS1-110 [G>A]) using the SpRY-ABE8e base editor. RNA delivery of the base editing system was safe and led to ∼80% of gene correction in the HSPCs of patients with BT without causing dangerous double-strand DNA breaks. In HSPC-derived erythroid populations, this strategy was able to restore β-globin production and correct inefficient erythropoiesis typically observed in BT both in vitro and in vivo. In conclusion, this proof-of-concept study paves the way for the development of a safe and effective autologous gene therapy approach for BT.
Collapse
Affiliation(s)
- Giulia Hardouin
- Laboratory of Chromatin and Gene Regulation during Development, Imagine Institute, INSERM UMR1163, Paris Cité University, Paris, France
- Biotherapy Clinical Investigation Center, Necker Children's Hospital, Assistance Publique Hopitaux de Paris, Paris, France
- Human Lymphohematopoiesis Laboratory, Imagine Institute, INSERM UMR1163, Paris Cité University, Paris, France
| | - Panagiotis Antoniou
- Laboratory of Chromatin and Gene Regulation during Development, Imagine Institute, INSERM UMR1163, Paris Cité University, Paris, France
| | - Pierre Martinucci
- Laboratory of Chromatin and Gene Regulation during Development, Imagine Institute, INSERM UMR1163, Paris Cité University, Paris, France
| | - Tristan Felix
- Laboratory of Chromatin and Gene Regulation during Development, Imagine Institute, INSERM UMR1163, Paris Cité University, Paris, France
| | - Sandra Manceau
- Biotherapy Clinical Investigation Center, Necker Children's Hospital, Assistance Publique Hopitaux de Paris, Paris, France
| | - Laure Joseph
- Biotherapy Clinical Investigation Center, Necker Children's Hospital, Assistance Publique Hopitaux de Paris, Paris, France
- Biotherapy Department, Necker Children's Hospital, Assistance Publique Hopitaux de Paris, Paris, France
| | - Cécile Masson
- Bioinformatics Platform, Imagine Institute, INSERM UMR1163, Paris Cité University, Paris, France
| | - Samantha Scaramuzza
- San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy
| | - Giuliana Ferrari
- San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy
- Vita-Salute San Raffaele University, Milan, Italy
| | - Marina Cavazzana
- Biotherapy Clinical Investigation Center, Necker Children's Hospital, Assistance Publique Hopitaux de Paris, Paris, France
- Human Lymphohematopoiesis Laboratory, Imagine Institute, INSERM UMR1163, Paris Cité University, Paris, France
- Biotherapy Department, Necker Children's Hospital, Assistance Publique Hopitaux de Paris, Paris, France
| | - Annarita Miccio
- Laboratory of Chromatin and Gene Regulation during Development, Imagine Institute, INSERM UMR1163, Paris Cité University, Paris, France
| |
Collapse
|
11
|
Joseph L, Corbasson A, Manceau S, Khimoud D, Meunier B, Cheminet G, Lefrere F, Jannot AS, Lu E, Arlet JB. Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease. Br J Haematol 2023; 200:563-567. [PMID: 36354234 PMCID: PMC9877809 DOI: 10.1111/bjh.18547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 09/30/2022] [Accepted: 10/19/2022] [Indexed: 11/11/2022]
Abstract
Given the lack of information about safety of the COVID-19 vaccines for sickle cell disease (SCD) patients, we sought to determine whether COVID-19 vaccine was associated with subsequent hospital admission for vaso-occlusive events (VOEs). We included 402 patients with SCD, including 88 regularly transfused. As of July 31, 2021, 213 (53.0%) of them had received a least one dose of COVID vaccine (Pfizer 93.0%). We showed similar risk of hospital admission for a VOE among vaccinated patients (whether transfused or not) and among a control group of non-vaccinated patients matched for age, sex and genotype.
Collapse
Affiliation(s)
- Laure Joseph
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France.,Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France
| | - Anne Corbasson
- Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Sandra Manceau
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France.,Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France
| | - Djamal Khimoud
- Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Benoit Meunier
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Geoffrey Cheminet
- Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France.,Faculty of Medicine, Université de Paris Cité, Paris, France
| | - François Lefrere
- Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Anne-Sophie Jannot
- Faculty of Medicine, Université de Paris Cité, Paris, France.,Department of Medical Informatics, Biostatistics, and Public Health, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Estelle Lu
- Department of Medical Informatics, Biostatistics, and Public Health, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Jean-Benoît Arlet
- Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France.,Internal Medicine Department, French National Sickle Cell Disease Referral Center, Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Paris, France.,Faculty of Medicine, Université de Paris Cité, Paris, France.,INSERM U1163, CNRS 8254, Institut IMAGINE, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France
| |
Collapse
|
12
|
Sobrino S, Magnani A, Semeraro M, Martignetti L, Cortal A, Denis A, Couzin C, Picard C, Bustamante J, Magrin E, Joseph L, Roudaut C, Gabrion A, Soheili T, Cordier C, Lortholary O, Lefrere F, Rieux-Laucat F, Casanova JL, Bodard S, Boddaert N, Thrasher AJ, Touzot F, Taque S, Suarez F, Marcais A, Guilloux A, Lagresle-Peyrou C, Galy A, Rausell A, Blanche S, Cavazzana M, Six E. Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy. Cell Rep Med 2023; 4:100919. [PMID: 36706754 PMCID: PMC9975109 DOI: 10.1016/j.xcrm.2023.100919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 10/20/2022] [Accepted: 01/06/2023] [Indexed: 01/27/2023]
Abstract
X-linked chronic granulomatous disease (CGD) is associated with defective phagocytosis, life-threatening infections, and inflammatory complications. We performed a clinical trial of lentivirus-based gene therapy in four patients (NCT02757911). Two patients show stable engraftment and clinical benefits, whereas the other two have progressively lost gene-corrected cells. Single-cell transcriptomic analysis reveals a significantly lower frequency of hematopoietic stem cells (HSCs) in CGD patients, especially in the two patients with defective engraftment. These two present a profound change in HSC status, a high interferon score, and elevated myeloid progenitor frequency. We use elastic-net logistic regression to identify a set of 51 interferon genes and transcription factors that predict the failure of HSC engraftment. In one patient, an aberrant HSC state with elevated CEBPβ expression drives HSC exhaustion, as demonstrated by low repopulation in a xenotransplantation model. Targeted treatments to protect HSCs, coupled to targeted gene expression screening, might improve clinical outcomes in CGD.
Collapse
Affiliation(s)
- Steicy Sobrino
- Human Lymphohematopoiesis Laboratory, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Alessandra Magnani
- Biotherapy Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, AP-HP, INSERM, Paris, France
| | - Michaela Semeraro
- Clinical Investigation Center CIC 1419, Necker-Enfants Malades Hospital, GH Paris Centre, Université Paris Cité, AP-HP, Paris, France
| | - Loredana Martignetti
- Clinical Bioinformatics Laboratory, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Akira Cortal
- Clinical Bioinformatics Laboratory, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Adeline Denis
- Human Lymphohematopoiesis Laboratory, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Chloé Couzin
- Biotherapy Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, AP-HP, INSERM, Paris, France
| | - Capucine Picard
- Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, AP-HP, Université Paris Cité, Paris, France; Lymphocyte Activation and Susceptibility to EBV Infection Laboratory, INSERM UMR 1163, Imagine Institute, Paris, France; Centre de Références des Déficits Immunitaires Héréditaires (CEREDIH), Necker-Enfants Malades Hospital, AP-HP, Paris, France
| | - Jacinta Bustamante
- Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, AP-HP, Université Paris Cité, Paris, France; Human Genetics of Infectious Diseases Laboratory, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
| | - Elisa Magrin
- Biotherapy Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, AP-HP, INSERM, Paris, France
| | - Laure Joseph
- Biotherapy Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France
| | - Cécile Roudaut
- Biotherapy Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, AP-HP, INSERM, Paris, France
| | - Aurélie Gabrion
- Biotherapy Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, AP-HP, INSERM, Paris, France
| | - Tayebeh Soheili
- Human Lymphohematopoiesis Laboratory, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Corinne Cordier
- Plateforme de Cytométrie en Flux, Structure Fédérative de Recherche Necker, INSERM US24-CNRS UAR3633, Paris, France
| | - Olivier Lortholary
- Necker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, AP-HP, Université Paris Cité, Imagine Institute, Paris, France
| | - François Lefrere
- Biotherapy Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; Department of Adult Hematology, Necker-Enfants Malades Hospital, AP-HP, Paris, France
| | - Frédéric Rieux-Laucat
- Immunogenetics of Pediatric Autoimmune Diseases Laboratory, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Jean-Laurent Casanova
- Human Genetics of Infectious Diseases Laboratory, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
| | - Sylvain Bodard
- Department of Adult Radiology, Necker Enfants-Malades Hospital, AP-HP, Université Paris Cité, Paris, France; Laboratoire d'Imagerie Biomédicale, LIB, Sorbonne Université, CNRS, INSERM, Paris, France
| | - Nathalie Boddaert
- Département de Radiologie Pédiatrique, INSERM UMR 1163 and UMR 1299, Imagine Institute, AP-HP, Necker-Enfants Malades Hospital, Paris, France
| | - Adrian J Thrasher
- UCL Great Ormond Street Institute of Child Health, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Fabien Touzot
- Biotherapy Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, AP-HP, INSERM, Paris, France
| | - Sophie Taque
- CHU de Rennes, Département de Pédiatrie, Rennes, France
| | - Felipe Suarez
- Necker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, AP-HP, Université Paris Cité, Imagine Institute, Paris, France; Imagine Institute, Université Paris Cité, Paris, France
| | - Ambroise Marcais
- Necker-Pasteur Center for Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, AP-HP, Université Paris Cité, Imagine Institute, Paris, France
| | - Agathe Guilloux
- Mathematics and Modelization Laboratory, CNRS, Université Paris-Saclay, Université d'Evry, Evry, France
| | - Chantal Lagresle-Peyrou
- Human Lymphohematopoiesis Laboratory, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France; Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, AP-HP, INSERM, Paris, France
| | - Anne Galy
- Genethon, Evry-Courcouronnes, France; Université Paris-Saclay, University Evry, Inserm, Genethon (UMR_S951), Evry-Courcouronnes, France
| | - Antonio Rausell
- Clinical Bioinformatics Laboratory, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France; Service de Médecine Génomique des Maladies Rares, AP-HP, Necker-Enfants Malades Hospital, Paris, France
| | - Stephane Blanche
- Department of Pediatric Immunology, Hematology, and Rheumatology, Necker-Enfants Malades Hospital, AP-HP, Paris, France
| | - Marina Cavazzana
- Biotherapy Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, AP-HP, INSERM, Paris, France; Imagine Institute, Université Paris Cité, Paris, France.
| | - Emmanuelle Six
- Human Lymphohematopoiesis Laboratory, Université Paris Cité, Imagine Institute, INSERM UMR 1163, Paris, France
| |
Collapse
|
13
|
Habibi A, Cannas G, Bartolucci P, Voskaridou E, Joseph L, Bernit E, Gellen-Dautremer J, Charneau C, Ngo S, Galactéros F. Outcomes of Pregnancy in Sickle Cell Disease Patients: Results from the Prospective ESCORT-HU Cohort Study. Biomedicines 2023; 11:biomedicines11020597. [PMID: 36831132 PMCID: PMC9953329 DOI: 10.3390/biomedicines11020597] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 02/09/2023] [Accepted: 02/11/2023] [Indexed: 02/19/2023] Open
Abstract
Sickle cell disease (SCD) refers to a group of inherited hemoglobin disorders in which sickle red blood cells display altered deformability, leading to a significant burden of acute and chronic complications, such as vaso-occlusive pain crises (VOCs). Hydroxyurea is a major therapeutic agent in adult and pediatric sickle cell patients. This treatment is an alternative to transfusion in some complications. Indeed, it increases hemoglobin F and has an action on the endothelial adhesion of red blood cells, leukocytes, and platelets. Although the safety profile of hydroxyurea (HU) in patients with sickle cell disease has been well established, the existing literature on HU exposure during pregnancy is limited and incomplete. Pregnancy in women with SCD has been identified as a high risk for the mother and fetus due to the increased incidence of maternal and non-fetal complications in various studies and reports. For women on hydroxyurea at the time of pregnancy, transfusion therapy should probably be initiated after pregnancy. In addition, there is still a significant lack of knowledge about the incidence of pregnancy, fetal and maternal outcomes, and management of pregnant women with SCD, making it difficult to advise women or clinicians on outcomes and best practices. Therefore, the objective of this study was to describe pregnancy outcomes (n = 128) reported in the noninterventional European Sickle Cell Disease COhoRT-HydroxyUrea (ES-CORT-HU) study. We believe that our results are important and relevant enough to be shared with the scientific community.
Collapse
Affiliation(s)
- Anoosha Habibi
- Sickle Cell Referral Center, Internal Medicine Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, U-PEC, 94000 Créteil, France
- INSERM-U955, Institut Mondor, Université Paris-Est Créteil, Team 2 Transfusion et Maladies du Globule Rouge, Laboratoire d’Excellence GR-Ex, 94000 Créteil, France
- Correspondence:
| | | | - Pablo Bartolucci
- Sickle Cell Referral Center, Internal Medicine Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, U-PEC, 94000 Créteil, France
- INSERM-U955, Institut Mondor, Université Paris-Est Créteil, Team 2 Transfusion et Maladies du Globule Rouge, Laboratoire d’Excellence GR-Ex, 94000 Créteil, France
| | - Ersi Voskaridou
- Thalassemia and Sickle Cell Disease Center, “Laiko” General Hospital, 115 27 Athens, Greece
| | - Laure Joseph
- Biotherapy Department, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris, 75610 Paris, France
| | - Emmanuelle Bernit
- Sickle Cell Referral Center, CHU Guadeloupe-Pôle Parents-Enfants—Hôpital Ricou, BP465, Pointe à Pitre, CEDEX, 97159 Guadeloupe, France
| | | | | | | | - Frédéric Galactéros
- Sickle Cell Referral Center, Internal Medicine Unit, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, U-PEC, 94000 Créteil, France
- INSERM-U955, Institut Mondor, Université Paris-Est Créteil, Team 2 Transfusion et Maladies du Globule Rouge, Laboratoire d’Excellence GR-Ex, 94000 Créteil, France
| |
Collapse
|
14
|
Flevari P, Voskaridou E, Galactéros F, Cannas G, Loko G, Joseph L, Bartolucci P, Gellen-Dautremer J, Bernit E, Charneau C, Habibi A. Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review. Biomedicines 2022; 10:biomedicines10123201. [PMID: 36551957 PMCID: PMC9775156 DOI: 10.3390/biomedicines10123201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 12/01/2022] [Accepted: 12/08/2022] [Indexed: 12/14/2022] Open
Abstract
The safety profile of hydroxyurea (HU) in patients with sickle-cell disease (SCD) is relatively well known. However, despite the suspected association of HU with myeloid neoplasms in myeloproliferative neoplasms (MPN), and the publication of sporadic reports of myeloid malignancies in SCD patients treated with HU, the possible excess risk imparted by HU in this population having an increasing life expectancy has failed to be demonstrated. Herein, we report one case of myelodysplastic syndrome emanating from the results on safety and effectiveness of HU on the largest European cohort of 1903 HU-treated adults and children who were followed-up prospectively in an observational setting over 10 years, accounting for a total exposure of 7309.5 patient-years. A comparison of this single case with previously published similar cases did not allow us to draw any significant conclusions due to the paucity of these events.
Collapse
Affiliation(s)
- Pagona Flevari
- Centre of Excellence in Rare Hematological Disease-Hemoglobinopathies, Laiko General Hospital, 11527 Athens, Greece
- Correspondence: (P.F.); (E.V.)
| | - Ersi Voskaridou
- Centre of Excellence in Rare Hematological Disease-Hemoglobinopathies, Laiko General Hospital, 11527 Athens, Greece
- Correspondence: (P.F.); (E.V.)
| | - Frédéric Galactéros
- Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, APHP, U-PEC, 94000 Créteil, France
| | - Giovanna Cannas
- Hospices Civils de Lyon, Edouard-Herriot Hospital, Internal Medicine, Reference Centre for Sickle-Cell Disease, Thalassemia and Other Red Blood Cell Disorders, 69003 Lyon, France
| | - Gylna Loko
- Martinique Hospital, 97212 Martinique, France
| | - Laure Joseph
- Biotherapy Department, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris, 75610 Paris, France
| | - Pablo Bartolucci
- Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, APHP, U-PEC, 94000 Créteil, France
| | - Justine Gellen-Dautremer
- Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, APHP, U-PEC, 94000 Créteil, France
| | - Emmanuelle Bernit
- Antilles-Guyane Reference Centre for Sickle-Cell Disease, Thalassemia and Other Red Blood Cell Disorders, Pointe à Pitre, 97157 Guadeloupe, France
| | - Corine Charneau
- Antilles-Guyane Reference Centre for Sickle-Cell Disease, Thalassemia and Other Red Blood Cell Disorders, Pointe à Pitre, 97157 Guadeloupe, France
| | - Anoosha Habibi
- Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, APHP, U-PEC, 94000 Créteil, France
| |
Collapse
|
15
|
Taniere P, Nicholson A, Gosney J, Joseph L, Shaw E, Lanctot A, Bains R, Ryan J. PATHways UK survey: Pathology perceptions on current biomarker testing and pathways for breast cancer in England. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01595-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
16
|
Sissoko A, Fricot-Monsinjon A, Roussel C, Manceau S, Dumas L, Capito C, Allali S, Yekkache N, Dussiot M, Nguyen Y, Des Ylouses AL, Aussilhou B, Tichit M, Hardy D, Maître B, Eckly A, De Montalembert M, Cavazzana M, Joseph L, Buffet P. Erythrocytic vacuoles that accumulate a fluorescent dye predict spleen size and function in sickle cell disease. Am J Hematol 2022; 97:E385-E388. [PMID: 36056794 PMCID: PMC9561039 DOI: 10.1002/ajh.26690] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 08/03/2022] [Accepted: 08/05/2022] [Indexed: 01/28/2023]
Affiliation(s)
- Abdoulaye Sissoko
- Université Paris Cité and Université des Antilles, Inserm, BIGR, F-75015, Paris, France
| | | | - Camille Roussel
- Université Paris Cité and Université des Antilles, Inserm, BIGR, F-75015, Paris, France
- Laboratoire d’Excellence GR-Ex, Paris, France
- Assistance publique des hôpitaux de Paris, Paris, France
| | - Sandra Manceau
- Laboratoire d’Excellence GR-Ex, Paris, France
- Assistance publique des hôpitaux de Paris, Paris, France
| | - Lucie Dumas
- Université Paris Cité and Université des Antilles, Inserm, BIGR, F-75015, Paris, France
- Laboratoire d’Excellence GR-Ex, Paris, France
| | - Carmen Capito
- Assistance publique des hôpitaux de Paris, Paris, France
| | - Slimane Allali
- Assistance publique des hôpitaux de Paris, Paris, France
| | - Narjis Yekkache
- Université Paris Cité and Université des Antilles, Inserm, BIGR, F-75015, Paris, France
| | - Michael Dussiot
- Université de Paris, U1163, Mécanismes cellulaires et moléculaires des désordres hématologiques et implications thérapeutiques, INSERM, Paris, France
| | - Yann Nguyen
- Assistance publique des hôpitaux de Paris, Paris, France
| | | | | | - Magali Tichit
- Institut Pasteur, Université de Paris, Unité Neuropathologie expérimentale, Paris, France
| | - David Hardy
- Institut Pasteur, Université de Paris, Unité Neuropathologie expérimentale, Paris, France
| | - Blandine Maître
- Université de Strasbourg, UMR_S1255, INSERM, Établissement Français du Sang-Grand Est, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | - Anita Eckly
- Université de Strasbourg, UMR_S1255, INSERM, Établissement Français du Sang-Grand Est, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France
| | | | | | - Laure Joseph
- Assistance publique des hôpitaux de Paris, Paris, France
| | - Pierre Buffet
- Université Paris Cité and Université des Antilles, Inserm, BIGR, F-75015, Paris, France
- Laboratoire d’Excellence GR-Ex, Paris, France
- Assistance publique des hôpitaux de Paris, Paris, France
| |
Collapse
|
17
|
Lascarrou JB, Dumas F, Bougouin W, Legriel S, Aissaoui N, Deye N, Beganton F, Lamhaut L, Jost D, Vieillard-Baron A, Nichol G, Marijon E, Jouven X, Cariou A, Agostinucci J, Aissaoui-Balanant N, Algalarrondo V, Alla F, Alonso C, Amara W, Annane D, Antoine C, Aubry P, Azoulay E, Beganton F, Billon C, Bougouin W, Boutet J, Bruel C, Bruneval P, Cariou A, Carli P, Casalino E, Cerf C, Chaib A, Cholley B, Cohen Y, Combes A, Coulaud J, Da Silva D, Das V, Demoule A, Denjoy I, Deye N, Diehl J, Dinanian S, Domanski L, Dreyfuss D, Dubois-Rande J, Dumas F, Duranteau J, Empana J, Extramiana F, Fagon J, Fartoukh M, Fieux F, Gandjbakhch E, Geri G, Guidet B, Halimi F, Henry P, Jabre P, Joseph L, Jost D, Jouven X, Karam N, Lacotte J, Lahlou-Laforet K, Lamhaut L, Lanceleur A, Langeron O, Lavergne T, Lecarpentier E, Leenhardt A, Lellouche N, Lemiale V, Lemoine F, Linval F, Loeb T, Ludes B, Luyt C, Mansencal N, Mansouri N, Marijon E, Maury E, Maxime V, Megarbane B, Mekontso-Dessap A, Mentec H, Mira J, Monnet X, Narayanan K, Ngoyi N, Perier M, Piot O, Plaisance P, Plaud B, Plu I, Raphalen J, Raux M, Revaux F, Ricard J, Richard C, Riou B, Roussin F, Santoli F, Schortgen F, Sharshar T, Sideris G, Spaulding C, Teboul J, Timsit J, Tourtier J, Tuppin P, Ursat C, Varenne O, Vieillard-Baron A, Voicu S, Wahbi K, Waldmann V. Differential Effect of Targeted Temperature Management Between 32 °C and 36 °C Following Cardiac Arrest According to Initial Severity of Illness: Insights From Two International Data Sets. Chest 2022; 163:1120-1129. [PMID: 36445800 DOI: 10.1016/j.chest.2022.10.023] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2022] [Revised: 10/10/2022] [Accepted: 10/23/2022] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Recent guidelines have emphasized actively avoiding fever to improve outcomes in patients who are comatose following resuscitation from cardiac arrest (ie, out-of-hospital cardiac arrest). However, whether targeted temperature management between 32 °C and 36 °C (TTM32-36) can improve neurologic outcome in some patients remains debated. RESEARCH QUESTION Is there an association between the use of TTM32-36 and outcome according to severity assessed at ICU admission using a previously derived risk score? STUDY DESIGN AND METHODS Data prospectively collected in the Sudden Death Expertise Center (SDEC) registry (France) between May 2011 and December 2017 and in the Resuscitation Outcomes Consortium Continuous Chest Compressions (ROC-CCC) trial (United States and Canada) between June 2011 and May 2015 were used for this study. Severity at ICU admission was assessed through a modified version of the Cardiac Arrest Hospital Prognosis (mCAHP) score, divided into tertiles of severity. The study explored associations between TTM32-36 and favorable neurologic status at hospital discharge by using multiple logistic regression as well as in tertiles of severity for each data set. RESULTS A total of 2,723 patients were analyzed in the SDEC data set and 4,202 patients in the ROC-CCC data set. A favorable neurologic status at hospital discharge occurred in 728 (27%) patients in the French data set and in 1,239 (29%) patients in the North American data set. Among the French data set, TTM32-36 was independently associated with better neurologic outcome in the tertile of patients with low (adjusted OR, 1.63; 95% CI, 1.15-2.30; P = .006) and high (adjusted OR, 1.94; 95% CI, 1.06-3.54; P = .030) severity according to mCAHP at ICU admission. Similar results were observed in the North American data set (adjusted ORs of 1.36 [95% CI, 1.05-1.75; P = .020] and 2.42 [95% CI, 1.38-4.24; P = .002], respectively). No association was observed between TTM32-36 and outcome in the moderate groups of the two data sets. INTERPRETATION TTM32-36 was significantly associated with a better outcome in patients with low and high severity at ICU admission assessed according to the mCAHP score. Further studies are needed to evaluate individualized temperature control following out-of-hospital cardiac arrest.
Collapse
Affiliation(s)
- Jean Baptiste Lascarrou
- Université Paris Cité, INSERM, PARCC, Paris, France; Médecine Intensive Réanimation, University Hospital Center, Nantes, France; AfterROSC Network Group, Paris, France.
| | - Florence Dumas
- Université Paris Cité, INSERM, PARCC, Paris, France; Emergency Department, Cochin University Hospital, APHP, Paris, France
| | - Wulfran Bougouin
- Université Paris Cité, INSERM, PARCC, Paris, France; AfterROSC Network Group, Paris, France; Medical-Surgical Intensive Care Unit, Hopital Privé Jacques Cartier, Massy, France
| | - Stephane Legriel
- Université Paris Cité, INSERM, PARCC, Paris, France; AfterROSC Network Group, Paris, France; Medical Surgical Intensive Care Unit, Mignot Hospital, Le Chesnay, France
| | - Nadia Aissaoui
- Université Paris Cité, INSERM, PARCC, Paris, France; AfterROSC Network Group, Paris, France; Medical Intensive Care Unit, Cochin Hospital (APHP) and University of Paris, Paris, France
| | - Nicolas Deye
- AfterROSC Network Group, Paris, France; Medical Intensive Care Unit, Lariboisière University Hospital, INSERM U942, Paris, France
| | | | - Lionel Lamhaut
- AfterROSC Network Group, Paris, France; SAMU de Paris-DAR Necker University Hospital-Assistance, Paris, France
| | - Daniel Jost
- Brigade des Sapeurs-Pompiers de Paris, Paris, France
| | - Antoine Vieillard-Baron
- Medical Intensive Care Unit, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt, France
| | - Graham Nichol
- University of Washington-Harborview Center for Prehospital Emergency Care, University of Washington, Seattle, WA
| | - Eloi Marijon
- Université Paris Cité, INSERM, PARCC, Paris, France
| | | | - Alain Cariou
- Université Paris Cité, INSERM, PARCC, Paris, France; AfterROSC Network Group, Paris, France; Medical Intensive Care Unit, Cochin Hospital (APHP) and University of Paris, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Cassidy M, Hayes R, Nevin R, Griffin A, Herbst J, Mealy B, Walsh K, Donnelly R, Harrison H, Jariol A, Joseph L, Carroll KM. 301 BENEFITS OF ENVIRONMENTAL MUSIC THERAPY IN AN ACUTE HOSPITAL. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Environmental Music Therapy (EMT) uses live music played by a music therapist to enhance the surrounding environment and is increasingly used in clinical settings. Studies show that EMT may reduce anxiety, enhance wellbeing, promote better communication between patients and staff, and reduce patient perception of waiting times in hospital. We aimed to explore the benefit of EMT for older adults in a geriatric outpatient setting and on rehabilitation wards.
Methods
Harp music was played by a music therapist in the vicinity of ambulatory clinics and on rehabilitation wards for 4 hours per week (over a 2-day period) for 20 weeks. Music exposure on any given day was to an estimated 50 outpatients, as well as 50 people passing the vicinity or to about 30 patients on the rehabilitation ward. Music was selected and played in a dynamic process, responding to verbal and non-verbal reactions of patients, family, and staff. Voluntary responses were recorded and collated.
Results
There were 36 recorded responses and all reflected positively on EMT. Patients cited that the music created a welcoming space and stimulated interaction and conversation. Several patients waiting for their clinic appointment noted that it distracted from fearful expectation and was a source of comfort. Some commented that they felt more relaxed and that it reduced stress. On rehabilitation wards, patients found familiar music to be calming with nurses citing that it stimulated social interaction between patients, family and staff. Responses to EMT gave insights that resulted in patient referrals for music therapy.
Conclusion
Environmental music played by a music therapist was found to modify patient hospital experiences. In particular, it appeared to reduce self-perceived stress and stimulate positive social interaction and conversation. This supports the use of EMT to advance the integration of the arts for wellbeing in an acute hospital.
Collapse
Affiliation(s)
- M Cassidy
- St. James's Hospital Creative Life Centre, Mercer's Institute for Successful Ageing, , Dublin, Ireland
| | - R Hayes
- St. James's Hospital Creative Life Centre, Mercer's Institute for Successful Ageing, , Dublin, Ireland
| | - R Nevin
- St. James's Hospital Creative Life Centre, Mercer's Institute for Successful Ageing, , Dublin, Ireland
| | - A Griffin
- St. James's Hospital Occupational Therapy Department, , Dublin, Ireland
| | - J Herbst
- St. James's Hospital Medical Social Work Department, , Dublin, Ireland
| | - B Mealy
- St. James's Hospital Physiotherapy Department, , Dublin, Ireland
| | - K Walsh
- St. James's Hospital Speech and Language Therapy Department, , Dublin, Ireland
| | - R Donnelly
- St. James’s Hospital Medicine for the Elderly Department, , Dublin, Ireland
| | | | | | - L Joseph
- St. James’s Hospital Medicine for the Elderly Department, , Dublin, Ireland
| | - KM Carroll
- St. James's Hospital Creative Life Centre, Mercer's Institute for Successful Ageing, , Dublin, Ireland
| |
Collapse
|
19
|
Rambaud E, Ranque B, Tsiakyroudi S, Joseph L, Bouly N, Douard R, François A, Pouchot J, Arlet JB. Risks and Benefits of Prophylactic Transfusion before Cholecystectomy in Sickle Cell Disease. J Clin Med 2022; 11:jcm11143986. [PMID: 35887750 PMCID: PMC9319142 DOI: 10.3390/jcm11143986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 07/04/2022] [Accepted: 07/07/2022] [Indexed: 11/20/2022] Open
Abstract
Preoperative transfusion (PT) reduces acute postoperative vaso-occlusive events (VOE) in sickle cell disease (SCD), but exposes patients to alloimmunization, encouraging a recent trend towards transfusion sparing. The aim of this study was to investigate the benefit–risk ratio of PT before cholecystectomy on the occurrence of postoperative VOE. Adult SCD patients who underwent cholecystectomy between 2008 and 2019 in our center were included. Patients’ characteristics, collected retrospectively, were compared according to PT. A total of 79 patients were included, 66% of whom received PT. Gallbladder histopathology found chronic cholecystitis (97%) and gallstones (66%). Transfused patients underwent more urgent surgeries and had experienced more painful vaso-occlusive crises (VOC) in the month before surgery (p = 0.05). Four (8.5%) post-transfusion alloimmunizations occurred, and two of them caused a delayed hemolytic transfusion reaction (DHTR) (4.3%). The occurrence of postoperative VOE was similar between the groups (19.2% vs. 29.6%, p = 0.45). Though not statistically significant, a history of hospitalized VOC within 6 months prior to surgery seemed to be associated to postoperative VOE among non-transfused patients (75% vs. 31.6%, p = 0.10). PT before cholecystectomy exposes to risks of alloimmunization and DHTR that could be avoided in some patients. Recent VOCs appear to be associated with a higher risk of postoperative VOE and prompt the preemptive transfusion of these patients.
Collapse
Affiliation(s)
- Elise Rambaud
- Reference Center for Sickle Cell Disease, Thalassemia and Other Red Blood Cell and Erythropoiesis Diseases, Department of Internal Medicine, European Georges Pompidou University Hospital (AP-HP), European Georges Pompidou Hospital (AP-HP), Paris Cité University, F-75015 Paris, France; (B.R.); (J.P.); (J.-B.A.)
- Correspondence:
| | - Brigitte Ranque
- Reference Center for Sickle Cell Disease, Thalassemia and Other Red Blood Cell and Erythropoiesis Diseases, Department of Internal Medicine, European Georges Pompidou University Hospital (AP-HP), European Georges Pompidou Hospital (AP-HP), Paris Cité University, F-75015 Paris, France; (B.R.); (J.P.); (J.-B.A.)
| | - Sofia Tsiakyroudi
- Digestive Surgery Department, European Georges Pompidou University Hospital (AP-HP), F-75015 Paris, France; (S.T.); (R.D.)
| | - Laure Joseph
- Reference Center for Sickle Cell Disease, Thalassemia and Other Red Blood Cell and Erythropoiesis Diseases, Biotherapy Service, Necker Hospital (AP-HP), F-75015 Paris, France;
| | - Nathalie Bouly
- French Blood Establishment, F-75015 Paris, France; (N.B.); (A.F.)
| | - Richard Douard
- Digestive Surgery Department, European Georges Pompidou University Hospital (AP-HP), F-75015 Paris, France; (S.T.); (R.D.)
| | - Anne François
- French Blood Establishment, F-75015 Paris, France; (N.B.); (A.F.)
| | - Jacques Pouchot
- Reference Center for Sickle Cell Disease, Thalassemia and Other Red Blood Cell and Erythropoiesis Diseases, Department of Internal Medicine, European Georges Pompidou University Hospital (AP-HP), European Georges Pompidou Hospital (AP-HP), Paris Cité University, F-75015 Paris, France; (B.R.); (J.P.); (J.-B.A.)
| | - Jean-Benoît Arlet
- Reference Center for Sickle Cell Disease, Thalassemia and Other Red Blood Cell and Erythropoiesis Diseases, Department of Internal Medicine, European Georges Pompidou University Hospital (AP-HP), European Georges Pompidou Hospital (AP-HP), Paris Cité University, F-75015 Paris, France; (B.R.); (J.P.); (J.-B.A.)
| |
Collapse
|
20
|
Dhedin N, Chevillon F, Castelle M, Lavoipière V, Vasseur L, Dalle JH, Joseph L, Beckerich F, Buchbinder N, Coman T, Garban F, Ferster A, Nguyen S, Boissel N, Arlet JB, Pondarre C. HLA-matched related-donor hematopoietic stem cell transplantation is a suitable treatment in adolescents and adults with sickle cell disease: comparison of myeloablative and non-myeloablative approaches. Am J Hematol 2022; 97:E359-E362. [PMID: 35802796 DOI: 10.1002/ajh.26656] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Revised: 06/29/2022] [Accepted: 07/05/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Nathalie Dhedin
- Hematology Unit for Adolescents and Young Adults, Saint Louis Hospital, Paris, France
| | - Florian Chevillon
- Hematology Unit for Adolescents and Young Adults, Saint Louis Hospital, Paris, France
| | | | - Virginie Lavoipière
- Internal Medicine and Clinical Immunology, Conception Hospital, Marseille. France; Internal Medicine, Martigues Hospital, France
| | - Loic Vasseur
- Hematology Unit for Adolescents and Young Adults, Saint Louis Hospital, Paris, France
| | | | | | | | | | - Tereza Coman
- Department of Hematology, Gustave Roussy Hospital, Villejuif, France
| | | | - Alina Ferster
- Hemato-Oncology and Transplantation Unit, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - S Nguyen
- Department of Hematology, Pitié Salpetrière Hospital, Sorbonne University, Paris, France
| | - Nicolas Boissel
- Hematology Unit for Adolescents and Young Adults, Saint Louis Hospital, Paris, France
| | - Jean-Benoit Arlet
- French Sickle Cell Referral Center, Internal Medicine Department, Georges Pompidou European Hospital, and Université de Paris, Paris, France
| | - Corinne Pondarre
- Pediatric Department, Sickle Cell Referral Center, Centre Hospitalier Intercommunal de Créteil, France and Inserm U955, Université Paris XII, Créteil, France
| | | |
Collapse
|
21
|
Le Monnier O, Joseph L, Bodard S, Boudhabhay I. Hepato-splenic abscesses in a sickle cell disease patient. Am J Hematol 2022; 97:1118-1119. [PMID: 35567777 DOI: 10.1002/ajh.26597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Revised: 05/02/2022] [Accepted: 05/05/2022] [Indexed: 11/07/2022]
Affiliation(s)
- Ophélie Le Monnier
- Department of Nephrology and Transplantation, Necker Enfant-Malades University Hospital, Assistance Publique Des Hôpitaux de Paris, Paris, France
| | - Laure Joseph
- Sickle Cell Referral Centre, Necker Enfant-Malades University Hospital, Assistance Publique Des Hôpitaux de Paris, Paris, France
| | - Sylvain Bodard
- Department of Adult Radiology, Necker Enfant-Malades University Hospital, Assistance Publique Des Hôpitaux de Paris, Paris, France
- Sorbonne Université, CNRS, INSERM Laboratoire d'Imagerie Biomédicale, Paris, France
- Université Paris Cité, Paris, France
| | - Idris Boudhabhay
- Department of Nephrology and Transplantation, Necker Enfant-Malades University Hospital, Assistance Publique Des Hôpitaux de Paris, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
22
|
Arlet J, Lionnet F, Khimoud D, Joseph L, Montalembert M, Morisset S, Garou A, Cannas G, Cougoul P, Guitton C, Holvoet L, Odièvre M, Cheminet G, Bartolucci P, Santin A, Bernit E, Luna G. Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France. Am J Hematol 2022; 97:E86-E91. [PMID: 34882837 PMCID: PMC9011445 DOI: 10.1002/ajh.26432] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 12/05/2021] [Accepted: 12/06/2021] [Indexed: 01/28/2023]
Affiliation(s)
- Jean‐Benoît Arlet
- French Sickle Cell Referral Center France
- Internal Medicine Department, Georges Pompidou European Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
| | - François Lionnet
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Internal Medicine Department, Tenon Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Djamal Khimoud
- French Sickle Cell Referral Center France
- Internal Medicine Department, Georges Pompidou European Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
| | - Laure Joseph
- French Sickle Cell Referral Center France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Service de Biothérapie, Necker‐Enfants malades Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Mariane Montalembert
- French Sickle Cell Referral Center France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Department of General Pediatrics and Pediatric Infectious Diseases, Necker‐Enfants Malades Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | | | - Alain Garou
- French Sickle Cell Referral Center France
- Pediatric Department, Centre Hospitalier de Mayotte Rue de l'hôpital Mayotte France
| | - Giovanna Cannas
- French Sickle Cell Referral Center France
- Internal Medicine Department Hospices Civils Lyon France
| | - Pierre Cougoul
- French Sickle Cell Referral Center France
- Internal Medicine Department IUCT Oncopole, CHU de Toulouse France
| | - Corinne Guitton
- French Sickle Cell Referral Center France
- Pediatric Department, Bicetre Hospital, Bicêtre Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Laurent Holvoet
- French Sickle Cell Referral Center France
- Internal Medicine Department, Georges Pompidou European Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
- Pediatric Department, Robert Debré Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Marie‐Hélène Odièvre
- French Sickle Cell Referral Center France
- Internal Medicine Department, Georges Pompidou European Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
- Pediatric Department, Hôpital Armand Trousseau Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Geoffrey Cheminet
- French Sickle Cell Referral Center France
- Internal Medicine Department, Georges Pompidou European Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
| | - Pablo Bartolucci
- French Sickle Cell Referral Center France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Department of Internal Medicine, Mondor Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Aline Santin
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Internal Medicine Department, Tenon Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Emmanuelle Bernit
- French Sickle Cell Referral Center France
- Unité Transversale de la Drépanocytose CHU de Guadeloupe Pointe à Pitre France
| | - Gonzalo Luna
- French Sickle Cell Referral Center France
- AP‐HP/Universities/Inserm COVID‐19 Research Collaboration Paris France
- Department of Internal Medicine, Mondor Hospital Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | | |
Collapse
|
23
|
Zubiena L, Lewin O, Ogunfiditimi G, Coleman R, Phezulu J, Blackburn T, Joseph L. Development and testing of the Health Information Website Evaluation Tool (HIWET) – An inter-rater reliability analysis study. Physiotherapy 2022. [DOI: 10.1016/j.physio.2021.12.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
24
|
Magrin E, Semeraro M, Hebert N, Joseph L, Magnani A, Chalumeau A, Gabrion A, Roudaut C, Marouene J, Lefrere F, Diana JS, Denis A, Neven B, Funck-Brentano I, Negre O, Renolleau S, Brousse V, Kiger L, Touzot F, Poirot C, Bourget P, El Nemer W, Blanche S, Tréluyer JM, Asmal M, Walls C, Beuzard Y, Schmidt M, Hacein-Bey-Abina S, Asnafi V, Guichard I, Poirée M, Monpoux F, Touraine P, Brouzes C, de Montalembert M, Payen E, Six E, Ribeil JA, Miccio A, Bartolucci P, Leboulch P, Cavazzana M. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial. Nat Med 2022; 28:81-88. [PMID: 35075288 DOI: 10.1038/s41591-021-01650-w] [Citation(s) in RCA: 38] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 11/30/2021] [Indexed: 01/19/2023]
Abstract
Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) are the most prevalent monogenic disorders worldwide. Trial HGB-205 ( NCT02151526 ) aimed at evaluating gene therapy by autologous CD34+ cells transduced ex vivo with lentiviral vector BB305 that encodes the anti-sickling βA-T87Q-globin expressed in the erythroid lineage. HGB-205 is a phase 1/2, open-label, single-arm, non-randomized interventional study of 2-year duration at a single center, followed by observation in long-term follow-up studies LTF-303 ( NCT02633943 ) and LTF-307 ( NCT04628585 ) for TDT and SCD, respectively. Inclusion and exclusion criteria were similar to those for allogeneic transplantation but restricted to patients lacking geno-identical, histocompatible donors. Four patients with TDT and three patients with SCD, ages 13-21 years, were treated after busulfan myeloablation 4.6-7.9 years ago, with a median follow-up of 4.5 years. Key primary endpoints included mortality, engraftment, replication-competent lentivirus and clonal dominance. No adverse events related to the drug product were observed. Clinical remission and remediation of biological hallmarks of the disease have been sustained in two of the three patients with SCD, and frequency of transfusions was reduced in the third. The patients with TDT are all transfusion free with improvement of dyserythropoiesis and iron overload.
Collapse
Affiliation(s)
- Elisa Magrin
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Michaela Semeraro
- Centre d'Investigation Clinique-Unité de Recherche Clinique, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Université de Paris, Paris, France
| | - Nicolas Hebert
- Univ Paris Est Creteil, INSERM, EFS, IMRB, Créteil, France.,Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Laure Joseph
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Alessandra Magnani
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Anne Chalumeau
- IMAGINE Institute, Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Aurélie Gabrion
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Cécile Roudaut
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Jouda Marouene
- Centre d'Investigation Clinique-Unité de Recherche Clinique, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Francois Lefrere
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Jean-Sebastien Diana
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Adeline Denis
- IMAGINE Institute, Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Bénédicte Neven
- Pediatric Immunology and Hematology Department, Hôpital Necker Enfants-Malades, Paris, France
| | - Isabelle Funck-Brentano
- Pediatric Immunology and Hematology Department, Hôpital Necker Enfants-Malades, Paris, France
| | - Olivier Negre
- CEA, INSERM, Université Paris-Saclay, Division of Innovative Therapies, Institut François Jacob, Fontenay aux Roses, France.,Bluebird Bio, Inc., Cambridge, MA, USA
| | - Sylvain Renolleau
- Pediatric Intensive Care Unit, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Valentine Brousse
- Department of General Pediatrics and Pediatric Infectious Diseases, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Laurent Kiger
- Univ Paris Est Creteil, INSERM, EFS, IMRB, Créteil, France
| | - Fabien Touzot
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Catherine Poirot
- Department of Hematology, Fertility Preservation, Hôpital Saint Louis, Paris, France.,Sorbonne Université, Paris, France
| | - Philippe Bourget
- Pharmacy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Wassim El Nemer
- Institut National de la Transfusion Sanguine (INTS), Paris, France
| | - Stéphane Blanche
- Pediatric Immunology and Hematology Department, Hôpital Necker Enfants-Malades, Paris, France
| | - Jean-Marc Tréluyer
- Centre d'Investigation Clinique-Unité de Recherche Clinique, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Université de Paris, Paris, France
| | | | | | - Yves Beuzard
- Univ Paris Est Creteil, INSERM, EFS, IMRB, Créteil, France.,CEA, INSERM, Université Paris-Saclay, Division of Innovative Therapies, Institut François Jacob, Fontenay aux Roses, France
| | | | - Salima Hacein-Bey-Abina
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Vahid Asnafi
- Université de Paris, Institut Necker-Enfants Malades, INSERM U1151, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France
| | - Isabelle Guichard
- Service de Médecine Interne, Hôpital Nord, CHU de Saint-Étienne, Saint-Étienne, Paris, France
| | - Maryline Poirée
- Department of Pediatric Hematology-Oncology, Centre Hospitalier Universitaire Lenval, Nice, France
| | - Fabrice Monpoux
- Unité d'Hémato-Oncologie Infantile. Hôpital de l'Archet 2, Nice, France
| | - Philippe Touraine
- Department of Endocrinology and Reproductive Medicine, Assistance Publique-Hopitaux de Paris, La Pitié-Salpêtrière, and Sorbonne University, Pierre et Marie Curie School of Medicine, Paris, France
| | - Chantal Brouzes
- Laboratory of Onco-hematology, Hôpital Necker-Enfants Malades, Paris, France
| | - Mariane de Montalembert
- Department of General Pediatrics and Pediatric Infectious Diseases, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France
| | - Emmanuel Payen
- CEA, INSERM, Université Paris-Saclay, Division of Innovative Therapies, Institut François Jacob, Fontenay aux Roses, France
| | - Emmanuelle Six
- IMAGINE Institute, Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Jean-Antoine Ribeil
- Biotherapy Department, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Centre d'Investigation Clinique-Biothérapie, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.,Bluebird Bio, Inc., Cambridge, MA, USA
| | - Annarita Miccio
- IMAGINE Institute, Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Pablo Bartolucci
- Univ Paris Est Creteil, INSERM, EFS, IMRB, Créteil, France.,Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France
| | - Philippe Leboulch
- CEA, INSERM, Université Paris-Saclay, Division of Innovative Therapies, Institut François Jacob, Fontenay aux Roses, France. .,Genetics Division, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA.
| | - Marina Cavazzana
- Université de Paris, Paris, France. .,IMAGINE Institute, Université de Paris, Sorbonne Paris Cité, Paris, France. .,Biotherapy Department and Clinical Investigation Center, Assistance Publique Hopitaux de Paris, INSERM, Paris, France.
| |
Collapse
|
25
|
Corbasson A, Meunier B, Lecoeur E, Jannot A, Khimoud D, Namaoui W, Joseph L, Arlet J. Tolérance du vaccin anti-COVID19 chez les patients drépanocytaires adultes. Rev Med Interne 2021. [PMCID: PMC8610706 DOI: 10.1016/j.revmed.2021.10.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Introduction Les patients drépanocytaires adultes sont considérés depuis le début de l’épidémie comme plus fragiles face à la COVID-19. L’analyse de la littérature et des travaux Français montrent que les patients de génotype SC et les plus de 40 ans sont les plus à risque de développer des formes sévères. De plus, des crises vaso-occlusives (CVO) peuvent être provoquées par l’infection, ce qui conduit à des hospitalisations plus fréquentes dans cette population. La vaccination prioritaire a donc été recommandée. Cependant, la tolérance du vaccin n’a pas été étudiée dans cette population, notamment le risque de crise induite par l’inflammation ou la fièvre post-vaccinale. Nous avons souhaité étudier les complications liées au vaccins anti-COVID19 dans une cohorte consécutive de patients drépanocytaires adultes. Patients et méthodes Étude observationnelle rétrospective réalisée sur une cohorte de patients d’un centre de référence Français. Tous les patients de notre cohorte, vaccinés jusqu’au 31 juillet 2021, ont été rappelés systématiquement dans les 2 mois suivant leur injection pour connaître les effets secondaires des vaccins. En plus des effets secondaires attendus, était notifié s’ils avaient eu des CVO à domicile ou des hospitalisations dans les 21 jours suivant le vaccin. La prévalence de CVO hospitalisées a été comparée à celle survenue dans les 3 semaines chez tous les patients drépanocytaires non vaccinés, venus dans la même période en consultation ou hospitalisation de jour (HDJ) dans notre centre. Résultats Sur une cohorte active d’environ 300 patients, seuls 100 patients drépanocytaires (68 % homozygotes, 22 % de génotype SC ; 55 % de femmes) étaient vaccinés au 31/07/2021. 95 % ont reçu un schéma vaccinal complet. 93 patients ont reçu le vaccin Pfizer, 3 le Moderna, 4 l’Astra Zeneca. L’âge médian des sujets vaccinés était de 30 ans (extrêmes 18-67). L’incidence des hospitalisations dans les 3 semaines était de 12 % après la première dose : 9 CVO simples, une CVO avec syndrome thoracique aigu, une thrombose veineuse profonde dans le bras injecté, une CVO avec séquestration splénique et rupture de rate entraînant un décès. Parmi ces 12 patients, quatre avaient été vaccinés dans les 30 jours suivant une CVO hospitalisée (incluant le patient décédé, vacciné à la fin d’une hospitalisation pour CVO). Dans la même période, l’incidence des hospitalisations sur notre cohorte de patients vus en consultation ou HDJ était de 9 % à 3 semaines (27/285) (P = 0,58, comparaison non significative par rapport aux vaccinés). Des CVO gérées à domicile ont été rapportées par 4 patients ayant reçu leur première dose. Les autres complications les plus fréquentes survenant dans les 48 heures suivant la première injection vaccinale étaient les suivantes : douleur musculaire au point d’injection (31 %), asthénie (23 %), courbatures (13 %), céphalées (13 %), fièvre (12 %), [MOU1] [A2] frissons (3 %), nausées (2 %), douleurs oculaires (1 %), orgelet (1 %), règles très douloureuses (1 %), diarrhées (1 %), malaise (1 %), vertiges rotatoires (1 %). Parmi les patients avec fièvre, seuls 2/12 ont été hospitalisés pour CVO. Enfin, seuls deux des 78 patients ayant eu la deuxième injection (2,5 %) ont été hospitalisés dans les 3 semaines (2 CVO). [MOU1]Peut être pas pour l’abstract mais il faudrait regarder si la majortité de ces 12 patients avec fièvre ne sont pas ceux qui ont été hospitalisés. si c’est la cas on pourra rajouter une phrase en ce sens [A2]3 de ces patients ont fait une CVO et seulement 2 ont été hospitalisés. Conclusion La tolérance du vaccin anti-COVID19 est très acceptable chez le patient drépanocytaire adulte, avec des effets secondaires minimes, proches de ceux de la population générale. Nos résultats rassurent sur le risque potentiel de CVO nécessitant une hospitalisation induite par l’injection vaccinale, même si la prudence imposerait de se placer à distance d’une crise pour la réalisation du vaccin. Ces résultats devraient diminuer l’appréhension d’une population à risque de la COVID-19 mais réticente à la vaccination, comme le montre le taux insuffisant de patients vaccinés dans notre cohorte, pourtant régulièrement incités à se faire vacciner depuis mars 2021.
Collapse
|
26
|
Diana JS, Manceau S, Leblanc T, Magnani A, Magrin E, Bendavid M, Couzin C, Joseph L, Soulier J, Cavazzana M, Lefrère F. A new step in understanding stem cell mobilization in patients with Fanconi anemia: A bridge to gene therapy. Transfusion 2021; 62:165-172. [PMID: 34751952 DOI: 10.1111/trf.16721] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 10/14/2021] [Accepted: 10/15/2021] [Indexed: 11/27/2022]
Abstract
BACKGROUND Fanconi anemia (FA) is an inherited disorder characterized clinically by congenital abnormalities, progressive bone marrow failure (BMF), and a predisposition to malignancy. Gene therapy (GT) of FA, via the infusion of gene-corrected peripheral blood (PB) autologous hematopoietic stem cells (HSCs), may constitute a cure for BMF. GT bypasses the donor restrictions and adverse events associated with allogenic HSC transplantation. However, adequate harvesting of PB-HSCs is a crucial determinant of successful engraftment in gene therapy. Harvesting the low numbers of HSCs in patients with FA is particularly challenging. STUDY DESIGN AND METHODS This open-label phase I/II trial evaluates the feasibility and safety of co-administration of G-CSF and plerixafor in patients with FA for the mobilization and harvesting of peripheral HSCs, intending to use them in a gene therapy trial. Patients with mutations in the FANCA gene received two subcutaneous injections of G-CSF (6 μg/kg × 2/d from D1 to D8. Plerixafor (0.24 mg/kg/d) was administered 2 h before apheresis (from D5 onward). RESULTS CD34+ cells were mobilized for four patients quickly but transiently after the plerixafor injection. One patient had a CD34+ cell count of over 100/μl; the mobilization peaked 2 h after the injection and lasted for more than 9 h. There were no short-term adverse events associated with the mobilization or harvesting procedures. CONCLUSION Our data in patients with FA show that the mobilization of HSCs with G-CSF and plerixafor is safe and more efficient in younger individuals without BMF.
Collapse
Affiliation(s)
- Jean-Sébastien Diana
- Biotherapy Department, Hôpital Necker Enfants Malades, Asistance Publique-Hôpitaux de Paris, Universite de Paris, Paris, France
| | - Sandra Manceau
- Biotherapy Department, Hôpital Necker Enfants Malades, Asistance Publique-Hôpitaux de Paris, Universite de Paris, Paris, France
| | - Thierry Leblanc
- Pediatric Hematology Unit, Hôpital Robert Debré, Asistance Publique-Hôpitaux de Paris, Universite de Paris, Paris, France
| | - Alessandra Magnani
- Biotherapy Department, Hôpital Necker Enfants Malades, Asistance Publique-Hôpitaux de Paris, Universite de Paris, Paris, France
| | - Elisa Magrin
- Biotherapy Department, Hôpital Necker Enfants Malades, Asistance Publique-Hôpitaux de Paris, Universite de Paris, Paris, France
| | - Matthieu Bendavid
- Pediatric Immunology and Hematology Unit, Hôpital Necker, Asistance Publique-Hôpitaux de Paris, Universite de Paris, Paris, France
| | - Chloe Couzin
- Biotherapy Department, Hôpital Necker Enfants Malades, Asistance Publique-Hôpitaux de Paris, Universite de Paris, Paris, France
| | - Laure Joseph
- Biotherapy Department, Hôpital Necker Enfants Malades, Asistance Publique-Hôpitaux de Paris, Universite de Paris, Paris, France
| | - Jean Soulier
- Hematology Laboratory, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Universite de Paris, Paris, France
| | - Marina Cavazzana
- Biotherapy Department, Hôpital Necker Enfants Malades, Asistance Publique-Hôpitaux de Paris, Universite de Paris, Paris, France
| | - Francois Lefrère
- Biotherapy Department, Hôpital Necker Enfants Malades, Asistance Publique-Hôpitaux de Paris, Universite de Paris, Paris, France
| |
Collapse
|
27
|
Joseph L, Thuret I. Les alternatives médicamenteuses à la TF : anciennes et nouvelles molécules. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
28
|
Navarro I, Joseph L, Liu Z, Berlin A, Helou J, Raman S, Weersink R, Rink A, Lao B, Menard C, Chung P. Physician and Patient Reported Morbidity After MR-Guided Salvage Brachytherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Montalembert M, Voskaridou E, Oevermann L, Cannas G, Habibi A, Loko G, Joseph L, Colombatti R, Bartolucci P, Brousse V, Galactéros F. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. Am J Hematol 2021; 96:1223-1231. [PMID: 34224583 DOI: 10.1002/ajh.26286] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Accepted: 07/02/2021] [Indexed: 12/28/2022]
Abstract
Several controlled studies have evidenced good efficacy and short-term and mid-term safety profiles for hydroxyurea (HU), which has become the cornerstone for prevention of sickle-cell disease (SCD)-related vaso-occlusive crises. However, there are few large-scale reports on its long-term use and certain caregivers and patients have concerns about its safety. Following the licensing of HU in Europe for children and adults with severe forms of SCD, ESCORT-HU was designed as a Phase IV observational cohort study. It included 1906 participants, of whom 55% were adults. The most common hemoglobin (Hb) genotypes were HbSS (84.7%) and HbSβ+ (7.0%). The median duration of follow-up was 45 months, for a total of 7309 patient-years of observation. The dose of HU after 1 year was 20.6 mg/kg/d for children and 16.3 mg/kg/d for adults. There was a statistically significant decrease in the number of vaso-occlusive episodes lasting >48 h, acute chest syndrome episodes, hospitalizations, and the percentage of patients requiring blood transfusions within the first 12 months relative to the year before enrolment. Neutropenia and thrombocytopenia were the most commonly reported adverse effects. No new HU toxicity was identified. Overall, 125 pregnancies were reported in 101 women and no malformations were observed in the neonates. There were 12 pregnancies for partners of male patients treated with HU. One case of fatal myelodysplastic syndrome was reported, for which a causal association with HU could not be excluded. This cohort study of patients with SCD highlights the positive benefit-to-risk ratio of HU in children and adults.
Collapse
Affiliation(s)
- Mariane Montalembert
- Reference Centre for Sickle Cell Disease, Department of General Pediatrics and Pediatric Infectious Diseases Necker‐Enfants malades Hospital, Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Ersi Voskaridou
- Centre of Excellence in Rare Hematological Disease‐Hemoglobinopathies, Laiko General Hospital Athens Greece
| | - Lena Oevermann
- Department of Pediatric Oncology & Hematology Charité University Medicine, Berlin and Berlin Institute of Health Berlin Germany
| | - Giovanna Cannas
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Médecine Interne, Centre de Référence Constitutif: Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse Lyon France
| | - Anoosha Habibi
- Sickle Cell Referral Center, Department of Internal Medicine Henri‐Mondor University Hospital‐UPEC, AP‐HP Créteil France
| | - Gylna Loko
- Centre hospitalier de la Martinique Fort‐de‐France Martinique France
| | - Laure Joseph
- Biotherapy Department Necker Children's Hospital, Assistance Publique‐Hôpitaux de Paris Paris France
| | | | - Pablo Bartolucci
- Sickle Cell Referral Center, Department of Internal Medicine Henri‐Mondor University Hospital‐UPEC, AP‐HP Créteil France
| | - Valentine Brousse
- Reference Centre for Sickle Cell Disease, Department of General Pediatrics and Pediatric Infectious Diseases Necker‐Enfants malades Hospital, Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
| | - Frédéric Galactéros
- Sickle Cell Referral Center, Department of Internal Medicine Henri‐Mondor University Hospital‐UPEC, AP‐HP Créteil France
| | | |
Collapse
|
30
|
Diana JS, Manceau S, Rabeony T, Elie C, Jolaine V, Zamora S, Aubart M, Salvi N, Bodemer C, Bader-Meunier B, Barnerias C, Iserin F, Chardot C, Lacaille F, Renolleau S, Salomon R, Joseph L, Cavazzana M, Lefrere F, Dupic L, Delville M. Therapeutic plasma exchange for life-threatening pediatric disorders. J Clin Apher 2021; 36:823-830. [PMID: 34469617 DOI: 10.1002/jca.21934] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 07/12/2021] [Accepted: 08/17/2021] [Indexed: 01/04/2023]
Abstract
INTRODUCTION Therapeutic plasma exchange (TPE) is acknowledged to be an effective treatment in life-threatening pediatric disorders. Apheresis for pediatric diseases has been poorly investigated, and most studies to date featured small numbers of patients and lacked control groups. The objective of the present study was to evaluate the tolerance of TPE in pediatric patients. MATERIALS AND METHODS A retrospective cohort study via a web-based electronic case report form including pediatric patients referred for TPE between January 2005 and December 2014. RESULTS A total of 78 patients (median [range] age: 9.8 [0.53-17.93]) and 731 TPE procedures were analyzed. The indications were antibody-mediated rejection (n = 33; 42%) and desensitization therapy (n = 5; 6%) after solid organ or hematopoietic stem cell transplantation, thrombotic microangiopathy (n = 17; 22%), pediatric inflammatory diseases (n = 16; 21%), kidney diseases (n = 6; 8%), and hyperviscosity syndrome (n = 1; 1%). On average, each patient underwent six procedures during the first session [range: 1-19]. In the 2 weeks following the start of a session, 72 patients (92%) presented a total of 311 adverse events (AEs) potentially related to TPE. The risk of AEs was not related to the indication for TPE, the intensity of care, venous access, plasma substitute use, or body weight. None of the deaths was related to the TPE. CONCLUSION We studied one of the largest retrospective pediatric cohorts described to date. Our experience of TPE children's TPE feasibility concerned specific, life-threatening conditions and otherwise treatment-refractory diseases.
Collapse
Affiliation(s)
- Jean-Sebastien Diana
- Hôpital Necker Enfants Malades, Paris, France.,Université de Paris, Paris, France
| | - Sandra Manceau
- Hôpital Necker Enfants Malades, Paris, France.,Université de Paris, Paris, France
| | | | - Caroline Elie
- Université de Paris, Paris, France.,Institut Imagine, Paris, France
| | - Valerie Jolaine
- Université de Paris, Paris, France.,Institut Imagine, Paris, France
| | | | | | | | - Christine Bodemer
- Hôpital Necker Enfants Malades, Paris, France.,Université de Paris, Paris, France
| | | | | | | | - Christophe Chardot
- Hôpital Necker Enfants Malades, Paris, France.,Université de Paris, Paris, France
| | | | - Sylvain Renolleau
- Hôpital Necker Enfants Malades, Paris, France.,Université de Paris, Paris, France
| | - Remi Salomon
- Hôpital Necker Enfants Malades, Paris, France.,Université de Paris, Paris, France
| | | | - Marina Cavazzana
- Hôpital Necker Enfants Malades, Paris, France.,Université de Paris, Paris, France.,Institut Imagine, Paris, France
| | | | | | - Marianne Delville
- Hôpital Necker Enfants Malades, Paris, France.,Université de Paris, Paris, France.,Institut Imagine, Paris, France
| |
Collapse
|
31
|
Omar S, Ismail F, Joseph L, Ngcamu D, Okozi N, van der Meulen M, Gwala T, Bhyat Z, Sicwetsha A, de Abreu C, Danisa L, Makubalo L, Ismail N. Bedaquiline resistance and genetic resistance associated variants: South African National Bedaquiline Surveillance program 2014–2019. Int J Infect Dis 2020. [DOI: 10.1016/j.ijid.2020.09.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
32
|
Nichols M, Stevenson L, Koski L, Basler C, Wise M, Whitlock L, Francois Watkins L, Friedman CR, Chen J, Tagg K, Joseph L, Caidi H, Patel K, Tolar B, Hise K, Classon A, Ceric O, Reimschuessel R, Williams IT. Detecting national human enteric disease outbreaks linked to animal contact in the United States of America. REV SCI TECH OIE 2020; 39:471-480. [PMID: 33046928 DOI: 10.20506/rst.39.2.3098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Enteric pathogens, such as non-typhoidal Salmonella, Campylobacter and Escherichia coli, can reside in the intestinal tract of many animals, including livestock, companion animals, small mammals and reptiles. Often, these animals can appear healthy; nonetheless, humans can become infected after direct or indirect contact, resulting in a substantial illness burden. An estimated 14% of the 3.2 million illnesses that occur in the United States of America (USA) each year from such enteric pathogens are attributable to animal contact. Surveillance for enteric pathogens in the USA includes the compilation and interpretation of both laboratory and epidemiologic data. However, the authors feel that a collaborative, multisectoral and transdisciplinary - or One Health - approach is needed for data collection and analysis, at every level. In addition, they suggest that the future of enteric illness surveillance lies in the development of improved technologies for pathogen detection and characterisation, such as genomic sequencing and metagenomics. In particular, using whole-genome sequencing to compare genetic sequences of enteric pathogens from humans, food, animals and the environment, can help to predict antimicrobial resistance among these pathogens, determine their genetic relatedness and identify outbreaks linked to a common source. In this paper, the authors describe three recent, multi-state human enteric illness outbreaks linked to animal contact in the USA and discuss how integrated disease surveillance was essential to outbreak detection and response. Additional datasharing between public health and animal health laboratories and epidemiologists at the local, national, regional and international level may help to improve surveillance for emerging animal and human health threats and lead to new opportunities for prevention.
Collapse
|
33
|
El Hoss S, Cochet S, Godard A, Yan H, Dussiot M, Frati G, Boutonnat-Faucher B, Laurance S, Renaud O, Joseph L, Miccio A, Brousse V, Mohandas N, El Nemer W. Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease. Haematologica 2020; 106:2707-2719. [PMID: 32855279 PMCID: PMC8485663 DOI: 10.3324/haematol.2020.265462] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Indexed: 11/09/2022] Open
Abstract
While ineffective erythropoiesis has long been recognized as a key contributor to anemia in thalassemia, its role in anemia of sickle cell disease (SCD) has not been critically explored. Using in vitro and in vivo derived human erythroblasts we assessed the extent of ineffective erythropoiesis in SCD. Modeling the bone marrow hypoxic environment, we found that hypoxia induces death of sickle erythroblasts starting at the polychromatic stage, positively selecting cells with high levels of fetal hemoglobin (HbF). Cell death was associated with cytoplasmic sequestration of heat shock protein 70 and was rescued by induction of HbF synthesis. Importantly, we document that in bone marrow of SCD patients similar cell loss occurs during the final stages of terminal differentiation. Our study provides evidence for ineffective erythropoiesis in SCD and highlights an anti-apoptotic role for HbF during the terminal stages of erythroid differentiation. These findings imply that the beneficial effect on anemia of increased HbF levels is not only due to the increased life span of red cells but also a consequence of decreased ineffective erythropoiesis.
Collapse
Affiliation(s)
- Sara El Hoss
- Université de Paris, INSERM UMR_S 1134, Paris, France
| | | | - Auria Godard
- Inserm - INTS - University of Paris, Paris, France
| | - Hongxia Yan
- Red Cell Physiology Laboratory, New York Blood Center, New York, NY, USA
| | - Michaël Dussiot
- Imagine Institute, Université de Paris, Hopital Necker Enfants Malades, Paris, France
| | - Giacomo Frati
- Université de Paris, Imagine Institute, Paris, France
| | | | | | - Olivier Renaud
- Institut Curie, Paris Sciences et Lettres Research University, Paris, France
| | - Laure Joseph
- Service de biotherapie, Hôpital Universitaire Necker Enfants Malades, Paris, France
| | | | | | - Narla Mohandas
- Red Cell Physiology Laboratory, New York Blood Center, New York, NY, USA
| | | |
Collapse
|
34
|
Couzin C, Manceau S, Diana JS, Joseph L, Magnani A, Magrin E, Amrane H, Dupont E, Raphalen JH, Sibon D, Marcais A, Suarez F, Cavazzana M, Lefrère F, Delville M. Vascular access for optimal hematopoietic stem cell collection. J Clin Apher 2020; 36:12-19. [PMID: 32854142 DOI: 10.1002/jca.21828] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 07/23/2020] [Accepted: 07/24/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Autologous and allogeneic hematopoietic stem cell transplantation of cytokine-mobilized peripheral blood stem cells (PBSCs) is increasingly used to treat patients with hematologic disorders. Different types of vascular access have been exploited for the apheresis procedure, including peripheral veins (PV) and central venous catheter (CVC). In some cases, PV access is unavailable. There are few published data on the efficiency and quality of harvesting with different types of vascular access. This study brings out complications and morbidity of this procedure linked to these different access. METHODS We performed a comparative, retrospective, single-center study of hematopoietic stem cell collection using these two types of vascular access. We compared the efficiency and complication rate for 617 adults apheresis sessions in 401 patients and healthy donors, for PBSC collection via PV or CVC between 2010 and 2016. The quality of the HSC product was evaluated in terms of the total CD34 + count and neutrophil contamination. RESULTS The PV and CVC groups did not differ significantly in terms of the quality of the apheresis product, mean ± SD CD34 + cells collected in PV group was 383.1 ± 402.7 × 10e6 and 298.8 ± 372.7 × 10e6 and the level of neutrophil contamination was 21.0 ± 17.8% in the PV group and 20.6 ± 18.4% in the CVC group. The complication rate did not differ between the two groups. CONCLUSION The type of vascular access for apheresis hematopoietic stem cell harvesting must be determined by trained staff. Successful harvesting can be performed via PV then CVC is not needed or not available.
Collapse
Affiliation(s)
- Chloé Couzin
- Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France.,Paris Descartes University, Paris, France
| | - Sandra Manceau
- Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jean-Sébastien Diana
- Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France.,Paris Descartes University, Paris, France
| | - Laure Joseph
- Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France
| | - Alessandra Magnani
- Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France
| | - Elisa Magrin
- Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France
| | - Horiya Amrane
- Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Emilie Dupont
- Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jean-Herlé Raphalen
- Intensive Care Unit, Necker-Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - David Sibon
- Haematology Department, Necker-Children's Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Ambroise Marcais
- Haematology Department, Necker-Children's Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Felipe Suarez
- Paris Descartes University, Paris, France.,Haematology Department, Necker-Children's Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Marina Cavazzana
- Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France.,Paris Descartes University, Paris, France
| | - François Lefrère
- Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France
| | - Marianne Delville
- Biotherapy Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, Paris, France.,Paris Descartes University, Paris, France
| |
Collapse
|
35
|
Arlet JB, de Luna G, Khimoud D, Odièvre MH, de Montalembert M, Joseph L, Chantalat-Auger C, Flamarion E, Bartolucci P, Lionnet F, Monnier S, Guillaumat C, Santin A. Prognosis of patients with sickle cell disease and COVID-19: a French experience. Lancet Haematol 2020; 7:e632-e634. [PMID: 32563282 PMCID: PMC7302791 DOI: 10.1016/s2352-3026(20)30204-0] [Citation(s) in RCA: 76] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Revised: 06/09/2020] [Accepted: 06/12/2020] [Indexed: 11/24/2022]
Affiliation(s)
- Jean-Benoît Arlet
- French Sickle Cell Referral Centre, Department of Internal Medicine, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France.
| | - Gonzalo de Luna
- French Sickle Cell Referral Centre, Mondor Hospital, AP-HP, Creteil, France
| | - Djamal Khimoud
- French Sickle Cell Referral Centre, Department of Internal Medicine, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France
| | | | | | - Laure Joseph
- French Sickle Cell Referral Centre, Necker-Enfants malades Hospital, AP-HP, Paris, France
| | | | - Edouard Flamarion
- French Sickle Cell Referral Centre, Department of Internal Medicine, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France
| | - Pablo Bartolucci
- French Sickle Cell Referral Centre, Mondor Hospital, AP-HP, Creteil, France
| | - François Lionnet
- Internal Medicine Department, Tenon Hospital, APHP, Paris, France
| | - Sebastien Monnier
- Internal medicine Department, Centre Hospitalier de Versailles, Versailles, France
| | - Cécile Guillaumat
- Department of Paediatrics, Hôpital du Sud Francilien, Corbeil-Essonnes, France
| | - Aline Santin
- Internal Medicine Department, Tenon Hospital, APHP, Paris, France
| |
Collapse
|
36
|
Shamriz O, Simon AJ, Lev A, Megged O, Ledder O, Picard E, Joseph L, Molho-Pessach V, Tal Y, Millman P, Slae M, Somech R, Toker O, Berger M. Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation. Clin Exp Immunol 2020; 200:215-227. [PMID: 32201938 DOI: 10.1111/cei.13432] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Revised: 03/04/2020] [Accepted: 03/16/2020] [Indexed: 12/27/2022] Open
Abstract
Capping protein regulator and myosin 1 linker 2 (CARMIL2) deficiency is characterized by impaired T cell activation, which is attributed to defective CD28-mediated co-signaling. Herein, we aimed to analyze the effect of exogenous interleukin (IL)-2 on in-vitro T cell activation and proliferation in a family with CARMIL2 deficiency. This study included four children (one male and three females; aged 2·5-10 years at presentation). The patients presented with inflammatory bowel disease and recurrent viral infections. Genetic analysis revealed a novel homozygous 25-base pairs deletion in CARMIL2. Immunoblotting demonstrated the absence of CARMIL2 protein in all four patients and confirmed the diagnosis of CARMIL2 deficiency. T cells were activated in-vitro with the addition of IL-2 in different concentrations. CD25 and interferon (IFN)-γ levels were measured after 48 h and 5 days of activation. CD25 surface expression on activated CD8+ and CD4+ T cells was significantly diminished in all patients compared to healthy controls. Additionally, CD8+ T cells from all patients demonstrated significantly reduced IFN-γ production. When cells derived from CARMIL2-deficient patients were treated with IL-2, CD25 and IFN-γ production increased in a dose-dependent manner. T cell proliferation, as measured by Cell Trace Violet, was impaired in one patient and it was also rescued with IL-2. In conclusion, we found that IL-2 rescued T cell activation and proliferation in CARMIL2-deficient patients. Thus, IL-2 should be further studied as a potential therapeutic modality for these patients.
Collapse
Affiliation(s)
- O Shamriz
- The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel.,Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - A J Simon
- Sheba Cancer Research Center and Institute of Hematology, Sheba Medical Center, Tel HaShomer, Ramat-Gan, Israel
| | - A Lev
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Pediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Affiliated with Tel Aviv University, Tel Aviv, Israel
| | - O Megged
- Pediatric Infectious diseases Unit, Shaare Zedek Medical Center, Jerusalem, Israel
| | - O Ledder
- Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, Jerusalem, Israel
| | - E Picard
- Pediatric pulmonology Unit, Shaare Zedek Medical Center, Jerusalem, Israel
| | - L Joseph
- Pediatric pulmonology Unit, Shaare Zedek Medical Center, Jerusalem, Israel
| | - V Molho-Pessach
- Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - Y Tal
- Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - P Millman
- Pediatric Gastroenterology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - M Slae
- Pediatric Gastroenterology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - R Somech
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Pediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Affiliated with Tel Aviv University, Tel Aviv, Israel
| | - O Toker
- Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.,Allergy and Clinical Immunology Unit, Shaare Zedek Medical Center, Jerusalem, Israel
| | - M Berger
- The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel
| |
Collapse
|
37
|
Sitilertpisan P, Joseph L, Paungmali A, Paungmali U, Chunchai T. Investigation of the Contraction Ratio of Transversus Abdominis and Internal Oblique Muscles during Lumbopelvic Stability Test. Muscles Ligaments Tendons J 2020. [DOI: 10.32098/mltj.01.2020.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- P. Sitilertpisan
- Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiangmai, Thailand
| | - L. Joseph
- School of Health Science, University of Brighton, East Sussex, United Kingdom
| | - A. Paungmali
- Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiangmai, Thailand
| | - U. Paungmali
- Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiangmai, Thailand
| | - T. Chunchai
- Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiangmai, Thailand
| |
Collapse
|
38
|
Bougouin W, Dumas F, Lamhaut L, Marijon E, Carli P, Combes A, Pirracchio R, Aissaoui N, Karam N, Deye N, Sideris G, Beganton F, Jost D, Cariou A, Jouven X, Adnet F, Agostinucci JM, Aissaoui-Balanant N, Algalarrondo V, Alla F, Alonso C, Amara W, Annane D, Antoine C, Aubry P, Azoulay E, Beganton F, Benhamou D, Billon C, Bougouin W, Boutet J, Bruel C, Bruneval P, Cariou A, Carli P, Casalino E, Cerf C, Chaib A, Cholley B, Cohen Y, Combes A, Crahes M, Da Silva D, Das V, Demoule A, Denjoy I, Deye N, Dhonneur G, Diehl JL, Dinanian S, Domanski L, Dreyfuss D, Duboc D, Dubois-Rande JL, Dumas F, Empana JP, Extramiana F, Fartoukh M, Fieux F, Gabbas M, Gandjbakhch E, Geri G, Guidet B, Halimi F, Henry P, Hidden Lucet F, Jabre P, Jacob L, Joseph L, Jost D, Jouven X, Karam N, Kassim H, Lacotte J, Lahlou-Laforet K, Lamhaut L, Lanceleur A, Langeron O, Lavergne T, Lecarpentier E, Leenhardt A, Lellouche N, Lemiale V, Lemoine F, Linval F, Loeb T, Ludes B, Luyt CE, Maltret A, Mansencal N, Mansouri N, Marijon E, Marty J, Maury E, Maxime V, Megarbane B, Mekontso-Dessap A, Mentec H, Mira JP, Monnet X, Narayanan K, Ngoyi N, Perier MC, Piot O, Pirracchio R, Plaisance P, Plu I, Raux M, Revaux F, Ricard JD, Richard C, Riou B, Roussin F, Santoli F, Schortgen F, Sharifzadehgan A, Sideris G, Spaulding C, Teboul JL, Timsit JF, Tourtier JP, Tuppin P, Ursat C, Varenne O, Vieillard-Baron A, Voicu S, Wahbi K, Waldmann V. Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest: a registry study. Eur Heart J 2019; 41:1961-1971. [DOI: 10.1093/eurheartj/ehz753] [Citation(s) in RCA: 98] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Revised: 03/26/2019] [Accepted: 10/01/2019] [Indexed: 11/13/2022] Open
Abstract
Abstract
Aims
Out-of-hospital cardiac arrest (OHCA) without return of spontaneous circulation (ROSC) despite conventional resuscitation is common and has poor outcomes. Adding extracorporeal membrane oxygenation (ECMO) to cardiopulmonary resuscitation (extracorporeal-CPR) is increasingly used in an attempt to improve outcomes.
Methods and results
We analysed a prospective registry of 13 191 OHCAs in the Paris region from May 2011 to January 2018. We compared survival at hospital discharge with and without extracorporeal-CPR and identified factors associated with survival in patients given extracorporeal-CPR. Survival was 8% in 525 patients given extracorporeal-CPR and 9% in 12 666 patients given conventional-CPR (P = 0.91). By adjusted multivariate analysis, extracorporeal-CPR was not associated with hospital survival [odds ratio (OR), 1.3; 95% confidence interval (95% CI), 0.8–2.1; P = 0.24]. By conditional logistic regression with matching on a propensity score (including age, sex, occurrence at home, bystander CPR, initial rhythm, collapse-to-CPR time, duration of resuscitation, and ROSC), similar results were found (OR, 0.8; 95% CI, 0.5–1.3; P = 0.41). In the extracorporeal-CPR group, factors associated with hospital survival were initial shockable rhythm (OR, 3.9; 95% CI, 1.5–10.3; P = 0.005), transient ROSC before ECMO (OR, 2.3; 95% CI, 1.1–4.7; P = 0.03), and prehospital ECMO implantation (OR, 2.9; 95% CI, 1.5–5.9; P = 0.002).
Conclusions
In a population-based registry, 4% of OHCAs were treated with extracorporeal-CPR, which was not associated with increased hospital survival. Early ECMO implantation may improve outcomes. The initial rhythm and ROSC may help select patients for extracorporeal-CPR.
Collapse
Affiliation(s)
- Wulfran Bougouin
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Medical-Surgical Intensive Care Unit, Ramsay Générale de Santé, Hôpital Privé Jacques Cartier, 6 Avenue du Noyer Lambert, 91300 Massy, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- AfterROSC network, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
| | - Florence Dumas
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Emergency Department, Cochin-Hotel-Dieu Hospital, APHP, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
| | - Lionel Lamhaut
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- AfterROSC network, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Intensive Care Unit - SAMU 75, Necker-Enfants-Malades Hospital, APHP, 149 Rue de Sèvres, 75015 Paris, France
| | - Eloi Marijon
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Cardiology Department, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France
| | - Pierre Carli
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Intensive Care Unit - SAMU 75, Necker-Enfants-Malades Hospital, APHP, 149 Rue de Sèvres, 75015 Paris, France
| | - Alain Combes
- Medical-Surgical Intensive Care Unit, iCAN, Institute of Cardiometabolism and Nutrition, Pitié-Salpétrière Hospital, APHP, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Romain Pirracchio
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Surgical ICU, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France
| | - Nadia Aissaoui
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- AfterROSC network, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Medical ICU, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France
| | - Nicole Karam
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Cardiology Department, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France
| | - Nicolas Deye
- AfterROSC network, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
- Medical ICU, Lariboisière Hospital, AP-HP, 2 Rue Ambroise Paré, 75010 Paris, France
| | - Georgios Sideris
- Cardiology Department, Lariboisière Hospital, AP-HP, 2 Rue Ambroise Paré, 75010 Paris, France
| | - Frankie Beganton
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
| | - Daniel Jost
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- Brigade de Sapeurs Pompiers de Paris (BSPP), 1 Place Jules Renard, 75017 Paris, France
| | - Alain Cariou
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- AfterROSC network, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Medical Intensive Care Unit, Cochin Hospital, APHP, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France
| | - Xavier Jouven
- Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, 56 rue Leblanc, 75787 Paris, France
- Paris Sudden Death Expertise Center, 56 rue Leblanc, 75787 Paris, France
- Université Paris Descartes-Sorbonne Paris Cité, 12 Rue de l'École de Médecine, 75006 Paris, France
- Cardiology Department, Georges Pompidou European Hospital, AP-HP, 20 Rue Leblanc, 75015 Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Diana JS, Albinni S, Slimani A, Trémolières P, Marcais A, Suarez F, Pirenne F, Levy R, Neven B, Blanche S, Delville M, Joseph L, Cavazzana M, Lefrère F. CPA, absorbsion des Ac anti-HLA et désensibilisation en contexte de greffe hapoloidentique. Transfus Clin Biol 2019. [DOI: 10.1016/j.tracli.2019.06.309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Sanmamed N, Glicksman R, Heaton J, Herrera-Caceres J, Joseph L, Hansen A, Chung P, Finelli A, Fleshner N, Berlin A. Use of Combined Hormone Therapy with Post-Operative Radiation Treatment for Prostate Cancer: Impact of Randomized Trials On Clinical Practice. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
41
|
Hopman WM, Berger C, Joseph L, Morin SN, Towheed T, Anastassiades T, Adachi JD, Hanley DA, Prior JC, Goltzman D. Longitudinal assessment of health-related quality of life in osteoporosis: data from the population-based Canadian Multicentre Osteoporosis Study. Osteoporos Int 2019; 30:1635-1644. [PMID: 31069440 DOI: 10.1007/s00198-019-05000-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Accepted: 04/22/2019] [Indexed: 01/22/2023]
Abstract
UNLABELLED Little is known about the association between health-related quality of life (HRQOL) and osteoporosis in the absence of fracture, and how HRQOL may change over time. This study provides evidence of substantially reduced HRQOL in women and men with self-reported and/or BMD-confirmed osteoporosis, even in the absence of fragility fracture. INTRODUCTION Fragility fractures have a detrimental effect on the health-related quality of life (HRQOL) of those with osteoporosis. Less is known about the association between HRQOL and osteoporosis in the absence of fracture. METHODS Canadian Multicentre Osteoporosis Study participants completed the SF-36, a detailed health questionnaire and measures of bone mineral density (BMD) at baseline and follow-up. We report the results of participants ≥ 50 years with 10-year follow-up. Self-reported osteoporosis at baseline and BMD-based osteoporosis at follow-up were ascertained. Multivariable linear regression models were developed for baseline SF-36 domains, component summaries, and change over time, adjusting for relevant baseline information. RESULTS Baseline data were available for 5266 women and 2112 men. Women in the osteoporosis group had substantially lower SF-36 baseline scores, particularly in the physically oriented domains, than those without osteoporosis. A similar but attenuated pattern was evident for the men. After 10-year follow-up (2797 women and 1023 men), most domain scores dropped for women and men regardless of osteoporosis status, with the exception of mentally-oriented ones. In general, a fragility fracture was associated with lower SF-36 scores and larger declines over time. CONCLUSIONS This study provides evidence of substantially reduced HRQOL in women and men with self-reported and/or BMD-confirmed osteoporosis, even in the absence of fragility fracture. HRQOL should be thoroughly investigated even prior to fracture, to develop appropriate interventions for all stages of the disease.
Collapse
Affiliation(s)
- W M Hopman
- Kingston General Health Research Institute, Kingston Health Sciences Centre, Kingston, Ontario, Canada.
- Department of Public Health Sciences, Faculty of Medicine, Queen's University, Kingston, Ontario, Canada.
| | - C Berger
- Research Institute of the McGill University Health Centre, Montreal, QC, Canada
| | - L Joseph
- Department of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada
| | - S N Morin
- Department of Medicine, McGill University, Montréal, QC, Canada
| | - T Towheed
- Division of Rheumatology, Department of Medicine, Queen's University, Kingston, ON, Canada
| | - T Anastassiades
- Division of Rheumatology, Department of Medicine, Queen's University, Kingston, ON, Canada
| | - J D Adachi
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - D A Hanley
- McCaig Institute for Bone & Joint Health, University of Calgary, Calgary, AB, Canada
| | - J C Prior
- Department of Medicine/Endocrinology, University of British Columbia, Vancouver, BC, Canada
| | - D Goltzman
- Department of Medicine, McGill University, Montréal, QC, Canada
| | | |
Collapse
|
42
|
Honsel V, Khimoud D, Ranque B, Offredo L, Joseph L, Pouchot J, Arlet J. Différences phénotypiques entre patients drépanocytaires adultes d’origine sub-Saharienne nés en France métropolitaine et nés en Afrique sub-Saharienne. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
43
|
Joseph L, Sundaramurthy A, Berlin A, Helou J, Menard C, Warde P, Catton C, Lao B, Bayley A, Rink A, Beiki-Ardakani A, Chung P. PV-0147 MRI-guided salvage HDR brachytherapy for locally recurrent prostate cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30567-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Khan Z, Ahmad S, Jeragh A, Alfouzan W, Al Foudri H, Hassan N, Asadzadeh M, Joseph L, Varghese S. First isolation of Ascotricha chartarum from bronchoalveolar lavage of two patients with pulmonary infections. New Microbes New Infect 2018; 28:11-16. [PMID: 30766685 PMCID: PMC6363919 DOI: 10.1016/j.nmni.2018.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 12/18/2018] [Accepted: 12/19/2018] [Indexed: 11/12/2022] Open
Abstract
Ascotricha chartarum is a rare human pathogen. We describe the isolation and characterization of A. chartarum from bronchoalveolar lavage samples of two patients with underlying pulmonary infections. The identity of both isolates was established by typical phenotypic characteristics and by sequencing of the internal transcribed spacer region and D1/D2 domains of recombinant DNA and β-tubulin gene fragment. The demonstration of branched, septate hyphae in direct microscopic examination of both the specimens and isolation of the fungus in pure cultures suggest its aetiologic role in the disease process. Because of phenotypic similarities of A. chartarum with Chaetomium spp. and other Chaetomium-like fungi, the application of molecular methods is needed for its accurate identification. Although in the absence of histopathologic evidence the aetiologic role of A. chartarum could not be established unequivocally, nonetheless, in view of the rarity of its isolation from clinical specimens and demonstration of hyphal elements in bronchoalveolar lavage sample, this report assumes considerable significance. It serves to create awareness about environmental fungi that previously have missed attention but may play a role in respiratory infections.
Collapse
Affiliation(s)
- Z Khan
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| | - S Ahmad
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| | - A Jeragh
- Department of Microbiology, , Al Adan Hospital, Kuwait
| | - W Alfouzan
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| | - H Al Foudri
- Critical Care and ECMO Unit, Anesthesia Department, Al Adan Hospital, Kuwait
| | - N Hassan
- Department of Microbiology, , Al Adan Hospital, Kuwait
| | - M Asadzadeh
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| | - L Joseph
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| | - S Varghese
- Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
| |
Collapse
|
45
|
Jeragh A, Ahmad S, Khan Z, Tarazi RY, Ajmi S, Joseph L, Varghese S, Vayalil S. Subcutaneous phaeohyphomycosis caused by Amesia atrobrunnea in Kuwait. J Mycol Med 2018; 29:193-197. [PMID: 30446389 DOI: 10.1016/j.mycmed.2018.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2018] [Revised: 09/10/2018] [Accepted: 10/29/2018] [Indexed: 11/26/2022]
Abstract
The recently described genus Amesia encompasses four species but only Amesia atrobrunnea (=Chaetomium atrobrunneum) is known to be pathogenic to humans. Here, we describe a case of subcutaneous phaeohyphomycosis in Kuwait in an apparently immunocompetent patient diagnosed by direct microscopy of the infected tissue and culture. The identity of A. atrobrunnea was established by typical morphological characteristics and by sequencing of internally transcribed spacer (ITS) region and D1/D2 domains of rDNA. To the best of our knowledge, this is the first report documenting etiologic role of this species in causing a locally invasive subcutaneous infection.
Collapse
Affiliation(s)
- A Jeragh
- Departments of Microbiology, Al Adan Hospital, Kuwait
| | - S Ahmad
- Department of Microbiology, Kuwait
| | - Z Khan
- Department of Microbiology, Kuwait; Mycology Reference Laboratory, Faculty of Medicine, Kuwait University, Kuwait.
| | - R Y Tarazi
- Cardiac surgery, Al Adan Hospital, Kuwait
| | - S Ajmi
- Departments of Microbiology, Al Adan Hospital, Kuwait
| | - L Joseph
- Department of Microbiology, Kuwait
| | | | - S Vayalil
- Mycology Reference Laboratory, Faculty of Medicine, Kuwait University, Kuwait
| |
Collapse
|
46
|
Affiliation(s)
- L Joseph
- Imperial College London, London, UK
| | - S Ismail
- Imperial College London, London, UK
| | | | - M Gunst
- Sydney Children's Hospital Network, Sydney, Australia
| | | | - M Harris
- Imperial College London, London, UK
| | - A Abbara
- Imperial College London, London, UK
| |
Collapse
|
47
|
Parikh S, Murray L, Kenning L, Bottomley D, Din O, Dixit S, Ferguson C, Handforth C, Joseph L, Mokhtar D, White L, Wright G, Henry A. Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer. Clin Oncol (R Coll Radiol) 2018; 30:548-555. [DOI: 10.1016/j.clon.2018.06.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 05/16/2018] [Accepted: 05/20/2018] [Indexed: 01/04/2023]
|
48
|
Ribeil J, Labopin M, Stanislas A, Deloison B, Lemercier D, Habibi A, Albinni S, Charlier C, Lortholary O, Lefrere F, De Montalembert M, Blanche S, Galactéros F, Tréluyer J, Gluckman E, Ville Y, Joseph L, Delville M, Benachi A, Cavazzana M. Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory. Am J Hematol 2018; 93:794-802. [PMID: 29603363 PMCID: PMC6001537 DOI: 10.1002/ajh.25097] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Revised: 03/21/2018] [Accepted: 03/22/2018] [Indexed: 02/02/2023]
Abstract
Sickle cell disease (SCD) in pregnancy can be associated with adverse maternal and perinatal outcomes. Furthermore, complications of SCD can be aggravated by pregnancy. Optimal prenatal care aims to decrease the occurrence of maternal and fetal complications. A retrospective, French, two-center study compared two care strategies for pregnant women with SCD over two time periods. In the first study period (2005-2010), the women were systematically offered prophylactic transfusions. In the second study period (2011-2014), a targeted transfusion strategy was applied whenever possible, and home-based prophylactic nocturnal oxygen therapy was offered to all the pregnant women. The two periods did not differ significantly in terms of the incidence of vaso-occlusive events. Maternal mortality, perinatal mortality, and obstetric complication rates were also similar in the two periods, as was the incidence of post-transfusion complications (6.1% in 2005-2010 and 1.3% in 2011-2014, P = .15), although no de novo alloimmunizations or delayed hemolysis transfusion reactions were observed in the second period. The results of this preliminary, retrospective study indicate that targeted transfusion plus home-based prophylactic nocturnal oxygen therapy is safe and may decrease transfusion requirements and transfusion-associated complications.
Collapse
Affiliation(s)
- Jean‐Antoine Ribeil
- Biotherapy DepartmentNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
- Biotherapy CIC, West University Hospital Group, Assistance Publique‐Hôpitaux de Paris, INSERMParisFrance
| | - Myriam Labopin
- Clinical Hematology and Cellular Therapy DepartmentSaint‐Antoine Hospital, Assistance Publique‐Hôpitaux de Paris, France ‐ INSERM UMRs 938, Pierre et Marie Curie University (UPMC, Paris VI)ParisFrance
| | - Aurélie Stanislas
- Biotherapy DepartmentNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
- Biotherapy CIC, West University Hospital Group, Assistance Publique‐Hôpitaux de Paris, INSERMParisFrance
| | - Benjamin Deloison
- Department of Obstetrics and Fetal MedicineNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
| | - Delphine Lemercier
- Department of Obstetrics and Fetal MedicineNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
| | - Anoosha Habibi
- Reference Center for Sickle Cell Disease, Henri Mondor Hospital, Assistance Publique‐Hôpitaux de ParisCréteilFrance
| | - Souha Albinni
- Necker Children's HospitalFrench Blood Establishment ‐ Ile de FranceParisFrance
| | - Caroline Charlier
- Necker Children's Hospital, Assistance Publique‐Hôpitaux de ParisNecker Pasteur Center for Infectious Diseases and Tropical MedicineParisFrance
| | - Olivier Lortholary
- Imagine InstituteParisFrance
- Necker Children's Hospital, Assistance Publique‐Hôpitaux de ParisNecker Pasteur Center for Infectious Diseases and Tropical MedicineParisFrance
- Paris Descartes UniversityParisFrance
| | - François Lefrere
- Biotherapy DepartmentNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
- Biotherapy CIC, West University Hospital Group, Assistance Publique‐Hôpitaux de Paris, INSERMParisFrance
| | - Mariane De Montalembert
- Reference Centre for Sickle Cell Disease, Pediatric DepartmentNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
| | - Stéphane Blanche
- Unit of Pediatric Immunology and HematologyNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
| | - Frédéric Galactéros
- Reference Center for Sickle Cell Disease, Henri Mondor Hospital, Assistance Publique‐Hôpitaux de ParisCréteilFrance
| | - Jean‐Marc Tréluyer
- Paris Descartes UniversityParisFrance
- Necker Children's Hospital, Assistance Publique‐Hôpitaux de ParisClinical Research Unit/Clinical Investigation CentreParisFrance
| | - Eliane Gluckman
- Saint‐Louis Hospital, Paris, France and Monaco Scientific CenterEurocord Monacord International Observatory on Sickle Cell DiseaseMonaco
| | - Yves Ville
- Department of Obstetrics and Fetal MedicineNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
| | - Laure Joseph
- Biotherapy DepartmentNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
| | - Marianne Delville
- Biotherapy DepartmentNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
| | - Alexandra Benachi
- Department of Obstetrics and Gynecology and Reproductive MedicineAntoine Béclère Hospital, Assistance Publique‐Hôpitaux de Paris, Université Paris SudClamartFrance
| | - Marina Cavazzana
- Biotherapy DepartmentNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
- Biotherapy CIC, West University Hospital Group, Assistance Publique‐Hôpitaux de Paris, INSERMParisFrance
- Paris Descartes UniversityParisFrance
- Unit of Pediatric Immunology and HematologyNecker Children's Hospital, Assistance Publique‐Hôpitaux de ParisParisFrance
- Saint‐Louis Hospital, Paris, France and Monaco Scientific CenterEurocord Monacord International Observatory on Sickle Cell DiseaseMonaco
| |
Collapse
|
49
|
Sanchez-Villavicencio ML, Elamer N, Joseph L, Saleem A, Hall B, Harris CS, Cuerrier A, Arnason JT, Haddad PS. Non-polar solvent fractions of Oplopanax horridus stimulate muscle glucose uptake and inhibit hepatocellular glucose-6-phosphatase enzyme activity. Am J Transl Res 2018. [DOI: 10.1055/s-0038-1644932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- ML Sanchez-Villavicencio
- CIHR Team in Aboriginal Antidiabetic Medicines
- Département de pharmacologie et physiologie, Université de Montréal, Montréal, QUEBEC, Canada
| | - N Elamer
- CIHR Team in Aboriginal Antidiabetic Medicines
- Département de pharmacologie et physiologie, Université de Montréal, Montréal, QUEBEC, Canada
| | - L Joseph
- CIHR Team in Aboriginal Antidiabetic Medicines
- Département de sciences biologiques, Université de Montréal, Montréal, QUEBEC, Canada
| | - A Saleem
- CIHR Team in Aboriginal Antidiabetic Medicines
- Department of Biology, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - B Hall
- CIHR Team in Aboriginal Antidiabetic Medicines
- Department of Biology, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - CS Harris
- CIHR Team in Aboriginal Antidiabetic Medicines
- Department of Biology, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - A Cuerrier
- CIHR Team in Aboriginal Antidiabetic Medicines
- Département de sciences biologiques, Université de Montréal, Montréal, QUEBEC, Canada
| | - JT Arnason
- CIHR Team in Aboriginal Antidiabetic Medicines
- Department of Biology, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
| | - PS Haddad
- CIHR Team in Aboriginal Antidiabetic Medicines
- Département de pharmacologie et physiologie, Université de Montréal, Montréal, QUEBEC, Canada
| |
Collapse
|
50
|
Salem A, Gorman D, Mistry H, Joseph L, Shah R, Valentine H, Jackson A, West C, Faivre-Finn C, O'Connor J, Asselin M. OC-0267: Technical and biological validation of hypoxia PET imaging using [18F]fluroazomycin (FAZA) in NSCLC. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30577-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|